OXUCT -103 Clinical Trial Protocol V 3.0 17 Feb 2023  Oxular Limited  
 Confidential  page 1 of 111 
  
Oxular Limited  
Clinical  Trial  Protocol  
Clinical Trial Protocol Title : 
A Multi -Center, Randomized , Two-Arm, Parallel -Group , Single -masked,  24-week, Clinical 
Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal 
Triamcinolone Acetonide Administered with the Oxulumis® Ophthalmic Administration 
Device  in Subjects with Diabetic Macular Edema  
Clinical Trial Reference Numb er: OXUCT -103 
Study Registry ID: [REMOVED]  
Investigational Product Name:  [CONTACT_680108]® device  in DME  
CT Version:  V3.0 
Date:  17 Feb 2023 
Sponsor:  
 Oxular Ltd.  
Magdalen Centre  
[ADDRESS_920116]  
OX4 4GA, [LOCATION_008]  
Email: OXUCT -[EMAIL_12974]   
Telephone: +44 (0)1865 636200  
Funding Source:  Oxular Ltd.  
Author(s):  
 PD Dr. med. Friedrich Asmus, MD,  
Chief Medical Officer  
 

OXUCT -[ADDRESS_920117] Information  for Medical Oversight :  
Oxular Medical Monitor - Clinical Development  
Oxul ar Limited , Magdalen Centre, [ADDRESS_920118] -[EMAIL_12974]  
 
Confidentiality Statement  
This document includes confidential and privileged information and data that contain trade 
secrets that are the property of Oxular Limited. This information shall not be made public 
without prior written permission of Oxular Limited. This document may be disclosed to and 
used by [CONTACT_347500] a clinical trial site, who are under a 
confidentiality agreement with Oxular Limited and/or the Contract Research Organization 
conducting this clini cal trial.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 3 of 111 Signatures  
I hereby [CONTACT_680057] I approve of this clinical trial protocol  and agree to comply with its 
terms as laid out in this document.  
Sponsor signatory:  
PD Dr. med.  Friedrich  Asmus,  MD 
Chief  Medical  Officer  
   
Name, Function (print)  Signature  [CONTACT_1782]  
I hereby [CONTACT_680057] I approve of this clinical trial protocol  and agree to comply with its 
terms as laid out in this document.  
Coordinating Principal Investigator:  
  
[CONTACT_5627] : 
Function:  
Organization:  
Address:  
Telephone:  
 Signature  [CONTACT_1782]  
I hereby [CONTACT_12007] I approve of this clinical trial protocol and agree to comply with its 
terms as laid out in this document.  
Principal Investigator:  
  
[CONTACT_5627]:  
Function:  
Organization:  
Address:  
Telephone:  
 Signature  [CONTACT_1782]  
 
  
2/17/[ADDRESS_920119] Central Subfield Thickness  
CTP Clinical Trial Protocol  
DME  Diabetic Macular Edema  
EDC  Electronic Data Capture  
EMA  European Medicines Agency  
EoS End of Study  
ETDRS  Early Treatment Diabetic Retinopathy Study  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HR High Resolution  
IB Investigator Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IFU Instruction for Use  
IOP Intraocular Pressure  
IRB Institutional/Independent Review Board  
ISO International Organization for Standards  
IVT Intravitreal  
MedDRA  Medical Dictionary for Regulatory Activities  
ME Macular Edema  
OXUCT -[ADDRESS_920120] -A Optical Coherence Tomography Angiography  
OU Oculus Uterque – Both Eyes  
PDR  Proliferative Diabetic Retinopathy  
PRP Panretinal Photocoagulation  
SAE  Serious Adverse Event  
SADE  Serious Adverse Device Effect  
SD-OCT  Spectral Domain Optical Coherence Tomography  
SE Study Eye  
S[LOCATION_003]R  Serious and Unexpected Suspected Adverse Reactio n 
TA Triamcinolone Acetonide  
TEAE  Treatment Emergent Non -Serious Adverse Effect  
UADE  Unanticipated Adverse Device Effect  
US FDA  [LOCATION_002] Food and Drug Administration  
VEGF  Vascular Endothelial Growth Factor  
  
OXUCT -[ADDRESS_920121] of Figures:  ................................ ................................ ................................ ...........................  [ADDRESS_920122] of Tables  ................................ ................................ ................................ ..............................  9 
1 Protocol Summary  ................................ ................................ ................................ ..... 10 
1.1 Synopsis  ................................ ................................ ................................ .....................  10 
1.2 Schema  ................................ ................................ ................................ .......................  26 
1.3 Schedule of Activities (SoA)  ................................ ................................ .....................  27 
2 Introduction  ................................ ................................ ................................ ...............  30 
2.1 Study Rationale  ................................ ................................ ................................ ..........  30 
2.2 Background  ................................ ................................ ................................ ................  31 
2.3 Preclinical Testing of the Oxulumis® Ophthalmic Administration Device  ...............  32 
2.4 Previous clinical experience  ................................ ................................ ......................  32 
2.4.1  Diabetic Macular Edema:  ................................ ................................ ..........................  33 
2.4.2  Suprachoroidal Administr ation of TA via Microcatheterization  ..............................  34 
2.5 Benefit/Risk Assessment  ................................ ................................ ...........................  36 
3 Objectives and Endpoints  ................................ ................................ ..........................  38 
3.1 Objectives  ................................ ................................ ................................ ..................  38 
3.1.1  Primary Objective  ................................ ................................ ................................ ..... 38 
3.1.2  Explorative Objective  ................................ ................................ ................................  38 
3.2 Endpoints  ................................ ................................ ................................ ...................  38 
3.2.1  Primary (Safety) Endpoints  ................................ ................................ .......................  38 
3.2.2  Exploratory Efficacy (and/or Safety) Endpoints  ................................ .......................  38 
4 Clinical Trial Design  ................................ ................................ ................................ . 39 
4.1 Overall Trial Design  ................................ ................................ ................................ .. 39 
4.2 Scientific Rationale for Study  Design  ................................ ................................ ....... 41 
4.2.1  Target Indication  ................................ ................................ ................................ ....... 41 
4.3 Justification of Dose  ................................ ................................ ................................ .. 41 
4.4 End-of-Study Definition  ................................ ................................ ............................  42 
5 Study Population  ................................ ................................ ................................ ....... 42 
5.1 Inclusion Criteria  ................................ ................................ ................................ ....... 42 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...... 43 
5.3 Lifestyle Considerations  ................................ ................................ ............................  45 
5.4 Screen Failures  ................................ ................................ ................................ ..........  46 
6 Study Intervention and Concomitant Therapi[INVESTIGATOR_014]  ................................ ........................  46 
6.1 Study Intervention Administered  ................................ ................................ ...............  46 
6.1.1  Oxulumis® Ophthalm ic Administration Device  ................................ ........................  46 
6.1.2  Triamcinolone acetonide (Triesence®) ................................ ................................ ...... 47 
6.1.3  Preparation, Handling, Storage, and Accountability  ................................ .................  47 
6.1.4  Assignment to Study Intervention  ................................ ................................ .............  48 
6.1.5  Masking  ................................ ................................ ................................ .....................  48 
6.1.6  Study Intervention Compliance  ................................ ................................ .................  48 
6.1.7  Dose Modification  ................................ ................................ ................................ ..... 48 
6.1.8  Follow -on Treatment  ................................ ................................ ................................ . 48 
6.1.9  Treatment for Complications of the Underlying Disease  ................................ ..........  49 
6.1.10  Continued Access to Study Intervention after the End of the Study  .........................  50 
6.1.11  Treatment Overdose  ................................ ................................ ................................ .. 50 
6.2 Prior and Concomitant Therapy  ................................ ................................ ................  50 
6.2.1  Permitted Medications and/or Treatments  ................................ ................................  [ADDRESS_920123] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 7 of 111 6.2.2  Prohibited Medications and/or Treatments  ................................ ...............................  [ADDRESS_920124] 
Discontinuation/Withdrawal  ................................ ................................ .....................  [ADDRESS_920125] Discontinuation/Withdrawal from the Study  ................................ ................  [ADDRESS_920126] to Follow -up ................................ ................................ ................................ ...... 54 
8 Study Assessments and Procedures  ................................ ................................ ...........  54 
8.1 Evaluations Performed During Investigational Visits  ................................ ...............  55 
8.1.1  Screening Visit (Visit 1, Days -21 through -2) ................................ .........................  55 
8.1.2  Baseline visit (Visit 2, Day 0)  ................................ ................................ ...................  55 
8.1.3  Visits 3 through 9 (Day 1 – Week 20) ................................ ................................ ....... 58 
8.1.4  End of study visit (Visit 10, Week 24± 5 days)  ................................ ........................  59 
8.1.5  Early termination (ET) visit  ................................ ................................ ......................  59 
8.1.6  Unscheduled visit  ................................ ................................ ................................ ...... 59 
8.2 Administrative and General/Baseline Procedures  ................................ .....................  [ADDRESS_920127]  ................................ ................................ ................................ .. 60 
8.2.4  Concomitant medica tion review  ................................ ................................ ................  60 
8.2.5  Weight, Height, Vital Signs  ................................ ................................ ......................  60 
8.2.6  Oxulumis® use to adm inister Triesence®................................ ................................ ... [ADDRESS_920128] Experience Assessment  ................................ ................................ ................  61 
8.2.8  Retinal physician’s Documentation and Assessment of the Administration procedure
 [ADDRESS_920129] Corrected Visual Acuity (BCVA)  ................................ ................................ ..... [ADDRESS_920130] collection  ................................ .............  65 
8.4.2  Safety laboratory tests  ................................ ................................ ...............................  65 
8.4.3  Height, Weight, Vital Si gns, and Blood Pressure  ................................ .....................  66 
8.5 Safety Reporting, Adverse Events (AEs), and Serious Adverse Events (SAEs) ....... 66 
8.5.1  Time Period and Frequency for Collecting AE and SAE Information  .....................  67 
8.5.2  Method of Detecting AEs and SAEs  ................................ ................................ .........  68 
8.5.3  Follow -up of A Es and SAEs  ................................ ................................ .....................  68 
8.5.4  Disease -related events and/or Disease -related outcomes not qualifying as AEs or 
SAEs  ................................ ................................ ................................ ..........................  [ADDRESS_920131] of Recruitment  ................................ ................................ ............................  83 
10.7.2  Study/Site Termination  ................................ ................................ .............................  83 
11 Safety: Events, Definitions and P rocedures  ................................ ..............................  84 
11.1 Emergency Contacts for Investigator Reporting of Safety Events  ............................  84 
11.2 Adverse Event (AE)  ................................ ................................ ................................ ... 84 
11.3 Device Adverse Event (AE) and Adverse Device Effect (ADE)  ..............................  85 
11.4 Device Deficiency  ................................ ................................ ................................ ..... 85 
11.4.1  Time Period for Detecting Device Deficiencies  ................................ .......................  85 
11.4.2  Follow -up of Device Deficiencies  ................................ ................................ .............  85 
11.4.3  Regulatory Reporting Requirements of for Device Deficiencies  ..............................  86 
11.5 Serious Adverse Event (SAE)  ................................ ................................ ...................  86 
11.6 Device SAE, SADE and [LOCATION_003]DE  ................................ ................................ ..............  88 
11.7 AE and SAE Recording  ................................ ................................ .............................  89 
11.7.1  Assessment of Intensity  ................................ ................................ .............................  90 
11.7.2  Assessment of Causality  ................................ ................................ ............................  91 
11.7.3  Assessment of the Outcome of Adverse Events  ................................ ........................  91 
11.7.4  Follow -up of AEs and SAEs  ................................ ................................ .....................  92 
12 Regulatory Reporting Requirements (Serious Safety Events, Safety Reporting in 
Clinical Investigations  of Medical Devices, and DSUR)  ................................ ..........  [ADDRESS_920132] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 9 of 111 12.1 Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  ................................ .... [ADDRESS_920133]’s Experience Assessment – Day 0, Visit 2  ................................ ...................  94 
Instructions for the site interviewer:  ................................ ................................ .........................  [ADDRESS_920134] (to be read to the subject by [CONTACT_20679]):  ..............................  [ADDRESS_920135]’s Experience Assessment – Day 1, Visit 3 through Week 4, Visit 5  ...........  97 
Instructions for site interviewer:  ................................ ................................ ..............................  [ADDRESS_920136] (to be read to th e subject by [CONTACT_20679]):  ..........................  97 
13.3 Retinal physician’s documentation and assessment of administration procedure  ..... [ADDRESS_920137] of Figures:  
Figure 1:  Study Flow Diagram  ................................ ................................ ................................ . [ADDRESS_920138] of Tables : 
 
Table [ADDRESS_920139] -103 Clinical Trial Protocol V 3.0 17 Feb 2023  Oxular Limited  
 Confidential  page 10 of 111 
 1 Protocol Summary  
1.1 Synopsis  
Title  A 24-week, Randomized, Two -Arm, Parallel -Group, Single -masked , 
Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels 
of Suprachoroidal Triamcinolone Acetonide Administered with the 
Oxulumis® Ophthalmic Administration in Subjects with Diabetic 
Macular Edema  
Sponsor  
Protocol #:  OXUCT -103 
Phase:  Exploratory Clinical Trial  – Phase 2  
Background and 
Rationale:  There remains a high unmet need for a safe and efficacious treatment 
for DME in selected patients. Currently approved treatments 
including intravitreal (IVT) steroid implants or IVT anti -VEGF 
treatments in DME may not show satisfactory and/or sustained 
enough improvement of the macular edema and of vision. With 
existing ophthalmic steroid treatments, visual benefits may be 
compromised by [CONTACT_680058], which often trigger 
additional drug treatments or even ocular surgeries, e.g., intraocular 
lens replacement surgery. Accordingly, there continue to be 
significant treatment challenges for the heterogenous population of 
patients with DME.  
The current clinical trial evaluates a novel microcatheterization 
approach for suprachoroidal steroid administrati on that has the 
potential to address challenges with respect to critical adverse events, 
efficacy, and durability of treatment compared to other currently 
applied treatment options, e.g., subtenon, or IVT administration of the 
same ophthalmic steroid suspe nsion.  
The proposed ophthalmic administration device (Oxulumis®) deploys 
an integrated, highly flexible, soft (atraumatic) microcatheter in the 
suprachoroidal space  through a minimally invasive, short (27G) 
insertion needle in the region of the pars plana,  typi[INVESTIGATOR_897] 4-7mm post 
OXUCT -[ADDRESS_920140], the illumination 
allows confirmation of microcatheter positioning in the 
suprachoroidal space. Drug delivery is achie ved via a low -volume 
administration of the triamcinolone acetonide suspension 
(Triesence®). The current trial evaluates two different dose levels to 
initially explore the safety of different administration volumes. The 
low dose is 2.4mg triamcinolone aceto nide (TA, 60µl of a 40mg/ml 
suspension). The mid -dose is 4.0mg TA (100µl of a 40mg/ml 
suspension) . 
In a compassionate use program in Switzerland, both dose levels of 
2.4mg and 4.0mg were applied in patients with cystoid macular 
edema (CME) or post -surgical inflammatory edema refractory to 
standard treatments. In this limited number of treatments so far, no 
safety concerns were observed.  
The current trial OXUCT -[ADDRESS_920141].  
It is anticipated that posterior deployment of the drug in the 
suprachoroidal space will lead to a safer, more tolerable, and effective 
treatment compared to IVT or subtenon administration.  An important  
success factor for a completed  Oxulumis® procedure is a controlled  
scleral engagement of the insertion needle of the ophthalmic 
administration device. In a subset of subjects  with more limited 
access to the orbita, enophthalmus, and/or a thick, opaque, 
hypermobile conjunctivas a small incision of  the conjunctiva may be 
needed to ensure  facilitated access and  full visibility through the 
scleral engagement phase  of the Oxulumis microcatheterization 
procedure . Depending on the expert assessment of the investigator at 
the screening visit, the procedure can either be performed,  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 12 of 111 a) in an in -clinic setting first . In case the study treatment cannot be 
administered  in this setting, the investigator can perform the 
procedural variant  with a conjunctival /tenon  incision . Activities for 
Visit 2 need to be completed  within 14 days  (for details on scheduling 
see Section 1.3). 
b) at the discretion of the investigator, the procedur e can be 
performed directly in an operating/procedure room, if  the procedural 
variant with the conjunctival/tenon  incision is likely to be needed.  
An operating/procedure room will allow for the setting for a 
conjunctival/tenon incision, which is typi[INVESTIGATOR_680030] -
office setting.  
As eligibility for this trial is based on limited or no response to 
standard treatments, this trial uses another dose level of TA 
suspension as a control rather than exposing subjects the same or a 
similar treatment that they already had failed to respond.  
The standard dose for IVT injection is 4.0mg. This dose level will be 
admini stered in the current trial in the mid -dose group. In addition, 
2.4mg TA will be used in the low dose group . In both dose groups, 
TA is expected to be administered closer to the location of the disease 
activity compared to other treatment approaches. Local  
concentrations of TA in the retinal tissues are expected to be higher 
compared to the same doses administered by [CONTACT_680059].  
Overall Design  Twenty -four (24) week, randomized, two -arm, single -masked, 
clinical trial  to evaluate safety, toler ability, and to explore the 
efficacy of  two dose levels of  suprachoroidal triamcinolone acetonide 
(TA) suspension (Triesence®, 2.4 mg , and 4.0mg ) administered using  
the Oxulumis® ophthalmic administration device in subjects with pre-
treated Diabetic Macular Edema . 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 13 of 111 A focus of this trial is to evaluate the feasibility , safety, and 
tolerability of the ophthalmic administration of a low and a mid -dose 
of suprachoroidal triamcinolone acetonide suspension (Triesence®) 
with the Oxulumis® in DME. In addition, for the two dose groups of 
the trial, efficacy data on visual and anatomic changes will be 
collected.  
To support the main objectives of this trial, a sample size of 
[ADDRESS_920142] to safety considerations including initial safety and feasibility 
experience with suprachoroidal administration procedure.  
After a screening period, approximately 20 eligible DME subjects 
will be randomized  and treated  using a 1:1 ratio to receive a single 
administration of one of two dose levels of TA (low dose, 2.4mg. or 
mid-dose, 4.0mg, respectively).  Subjects in whom  the procedure 
could not be completed,  and TA is not injected, will be replace d in 
order  to reach approximately 20 treated subjects.  
The follow -up period after treatment administration will be up to 
twenty -four (24) weeks.  
Clinical visits will occur on Day 0, Day 1, Week 1, Week 4, and then 
every four (4)  weeks thereafter for a total of twenty -four (24) weeks. 
From Week 4 on, subjects will be assessed for their need for 
follow -on treatment to determine the length of the trea tment interval.  
Treatment 
Arm Intervention  Subjects  
1 One treatment with suprachoroidal low 
dose (2.4mg ) triamcinolone acetonide  N=10  
2 One treatment with suprachoroidal 
mid-dose (4.0mg ) triamcinolone 
acetonide  N=[ADDRESS_920143] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 14 of 111 If subjects show a need for the next treatment of DME according to 
pre-specified criteria, participation in this clinical investigation will 
end, and an early termination/end of the study visit will be conducted 
at the respective visit date. In this case, the follow -up period will be 
shorter than 24 weeks.  
After completion of participation in this clinical trial, patients will 
continue treatment with therapeutic options determined by [CONTACT_680060] . 
Periodically, the coordinating investigator [INVESTIGATOR_680031], continue with changes, o r be terminated.  This review can also be 
performed  by a Safety Review Committee , which  includ es all active 
investigators in this trial.  
Objective(s):  Primary Objective : 
• To evaluate the safety and tolerability of two dose levels of  
triamcino lone acetonide administered with the Oxulumis® to the 
suprachoroidal space  in subjects with DME. 
Exploratory Objective : 
• To explore the efficacy  of two dose levels of triamcinolone 
acetonide  with respect to VA changes, edema control, and 
durability of the treatment effect of suprachoroidal triamcinolone 
acetonide suspension (Triesence®) in subjects with  DME. 
Endpoint(s):  Safety endpoint:  
The primary endpoint of this study is safety and tolerability as 
assessed by:  
1. Frequency of ocular and systemic adverse events ( treatment -
emergent serious adverse events  [SAEs] and treatment -
emergent non -serious adverse events [TEAEs])  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 15 of 111 2. Frequency of adverse device effects (ADEs, serious ADEs 
[SADEs])  
Exploratory efficacy (and/or safety) endpoints:  
1. Mean Change in BCVA (ETDRS) at all study visits through 
Week [ADDRESS_920144] 15 letters at all  study  visits 
through Week 24 compared to baseline  
3. Time to subjects requiring  follow -on treatment  
4. Mean Change in Central subfield thickness (CST) at all study 
visits through Week 24 compared to baseline.  
5. Mean Change in IOP at all study visits through Week  24 
compared to baseline  
Population 
Studied:  This study population will consist of adult male and female subjects 
who:  
• Have been diagnosed with Type 1 or Type 2 diabetes mellitus.  
• Have DME involving the center of the fovea with central 
subfield thickness (CST) in the study eye of:  
≥ 320 for males or ≥ 305 for females on Spectralis 
(Heidelberg) or  
≥ 305 for males or ≥ 290 for females with Cirrus (Zeiss) by 
[CONTACT_66309]-OCT.  
• Have BCVA of ≤73 letters (E TDRS, approximate Snellen 
equivalent of 20/40 or worse) at the screening in the study 
eye. 
• Have shown  short -lived,  limited , or no response  to prior 
therapy with ocular (e.g., IVT, or subtenon) injections of 
steroids and/ or anti -VEGF agents.  Short -lived in the context 
of this trial is defined as less than [ADDRESS_920145] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 16 of 111 • Have no structural deficit of the retina likely correlated to  
short -lived,  limited , or absent therapeutic response.  
• Study eye suitable for suprachoroidal injection, i.e., no 
relevan t structural abnormalities can be observed like 
choroidal coloboma, chorioretinal anastomosis, and extreme 
scleral thinning, or hypotony, amongst others.  
The study is planned to be conducted in the [LOCATION_002].  
Duration of Study:  There will be up to ten (10) clinic visits over 24 weeks (in addition to 
up to three [3] weeks of Screening , plus up to 14 days to complete the 
baseline  visit activitie s). 
Subjects who meet the criteria for follow -on treatment will end study 
participation with an earlier EoS Visit before week  24. 
Number of 
Subjects:  Approximately  20 subjects will  be randomized and treated using a 1:1 
ratio to two treatment  arms receiving either 2.4mg TA (low dose arm) 
or 4.0mg TA ( mid-dose arm) as  a single treatment  with triamcinolone 
acetonide (Triesence®) administered with the Oxulumis® to the 
suprachoroidal space of one eye, the study eye.  Subjects in whom the 
procedural attempts do no t result in administration of TA will be 
replaced  to reach a total of approximately 20 treated subjects.  
Eligibility:  Inclusion Criteria : 
Subjects will be eligible if they meet all the following inclusion 
criteria:  
1. Able to understand and sign an informed consent form.  
2. At least [ADDRESS_920146] DME involving the center of the fovea in the study eye 
with a central subfield thickness (CST)  on SD -OCT of: 
≥ 320 for males or ≥ 305 for females on Spectralis 
(Heidelberg)  or  
≥ 305 for males or ≥ 290 for females with Cirrus (Zeiss).  
OXUCT -[ADDRESS_920147] BCVA in the study eye of ≤73 ETDRS letters 
(approximate Snellen equivalent of 20/40 or worse) at the 
screening visit.  The el igibility will be assessed based on the 
ETDRS BCVA letter score.  
6. Short -lived, limited, or no response to prior ocular injection 
therapy ( e.g., IVT or subtenon) of steroids and/or anti -VEGF 
agents based on the investigator’s assessment. Short -lived in 
this trial is defined as less than 4 weeks.  
7. For women who are not postmenopausal ( i.e., at least12 
months of non -therapy -induced amenorrhea or surgically 
sterile (absence of ovaries and/or uterus) agreement to remain 
abstinent or use combined contraceptive meth ods that result in 
a failure rate of less than 1% per year  from the treatment visit 
(Day  0) until the end of trial participation , or for at least  
12 weeks from the treatment visit (D0), if study participation 
ends before Visit 7, Week 12 . Examples of contr aceptive 
methods with an expected failure rate of less than 1% per year 
include male sterilization, hormonal implants, proper use of 
combined oral or injected hormonal contraceptives, and 
certain intrauterine devices. Alternatively, two methods ( e.g., 
two barrier methods such as a condom and a cervical cap) 
may be combined to achieve a failure rate of less than 1% per 
year, barrier methods must always be supplemented with the 
use of a spermicide.  
8. Males must agree to use a barrier method of contraception  
from the treatment visit (Day  0) until the end of trial 
participation , or for at least  12 weeks from the treatment visit 
(D0), if study participation ends before Visit 7, Week 12.  
9. Subject must be willing not to participate in any other clinical 
trial incl uding an investigational medicinal product (IMP) or 
an investigational device until the end of the participation in 
this trial.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 18 of 111  Main Exclusion Criteria : 
Subjects will be eligible if they do not meet any of the following 
exclusion criteria:  
1. Presence of any significant ocular or non -ocular 
disease/disorder (or medication and/or laboratory test 
abnormalities) which, in the opi[INVESTIGATOR_680032], may either 
put the subject at risk because of participation in the trial, may 
influence the results of the trial, or the subject’s ability to 
participate in the trial.  
2. Macular edema considered due to a cause other than diabetes 
mellitus in the study eye.  
3. Condition, in the study eye, in which visual  acuity is not 
expected to improve from the resolution of macular edema 
(e.g., foveal atrophy, clinically relevant loss of ellipsoid zone, 
pi[INVESTIGATOR_396536], vitreomacular traction, or nonretinal 
causes) . 
4. Conditions, in the study eye, that may render t he 
suprachoroidal microcatheter insertion and deployment 
difficult or subject the patient to excessive risk of 
complications. Examples include but are not limited to  ocular 
surface disease with significant conjunctival edema and/or 
inflammation , ocular hyp otony, scleral staphylomas, 
necrotizing scleritis, scleral melting, excessive choroidal 
scarring e.g., associated with pan -retinal photocoagulation, 
amongst others.  
5. Macular laser photocoagulation or panretinal laser 
photocoagulation (PRP) in the study eye performed within 
sixteen (16) weeks prior to screening.  
6. Active proliferative diabetic retinopathy (PDR) or sequelae of 
PDR (including iris neovascularization, vitreous hemorrhage, 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 19 of 111 tractional retinal detachment, extensive scarring following 
PRP) at screenin g in the study eye.  
7. History of recurrent or active intraocular inflammation in 
either eye ( e.g., uveitis) within 12 weeks prior to screening.  
8. Infectious eye disease like infectious blepharitis, keratitis, or 
conjunctivitis in either eye within four (4) weeks of screening.  
9. IOP ≥ 22 mmHg, or glaucomatous disc changes ( i.e., a cup 
disc ratio greater than 0.8) in the study eye at screening.  
10. History of glaucoma surgery, and or anti -glaucoma therapy 
with more than two active substances (in separate or a 
combination preparation)  at the screening visit  are 
exclusionary.  
11. History of closed -angle glaucoma.  
12. IOP <6mmHg (hypotony) in the study eye at screening.  
13. Spherical equivalent of the refractive error of −6 diopters of 
myopia or worse (prior to cataract or re fractive surgery) at 
screening.  
14. Cataract or other media opacity that limits the ability to obtain 
the planned imaging assessments.  
15. History of retinal detachment.  
16. Subjects who were previously treated for DME in the study 
eye must not have received:  
a.) an intr avitreal anti -VEGF treatment within four (4) weeks 
before screening. The 4 week interval before screening is 
used for IVT bevacizumab, ranibizumab, aflibercept, 
brolucizumab, or faricimab ( i.e., a combined Anti -
VEGF/anti -Ang2 agent), as also inclusion crit erion No. [ADDRESS_920148] be met.  
b.) Prior treatment with SUSVIMO® (Port Delivery System ) 
implant at any time is exclusionary.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 20 of 111 c.) Intra - or periocular/subtenon triamcinolone acetonide 
suspension  within 12 weeks before screening.  
d.) Intravitreal dexa methasone implant  (Ozurdex®) within 
24 weeks before screening.  
e.) Prior treatment with longer duration implants ( e.g., 
fluocinolone acetonide IVT implant , e.g., Iluvien®) at any 
time is exclusionary.  
f.) Prior treatment with suprachoroidal steroids  (commercial, 
investigational, or off -label) at any time is exclusionary.  
17. Concurrent use of systemic glucocorticoid medications or 
systemic steroids within twelve (12) weeks before screening is 
exclusionary.  
Intranasal, inhaled, and extra -ocular topi[INVESTIGATOR_680033].  
18. Treatment with ocriplasmin (Jetrea®) at any time.  
19. History of vitreoretinal surgery (including surgery for retinal 
detachment or scleral buckle) in the study eye. Vitrectomy is 
only exclusionary, if within [ADDRESS_920149] surgery, or uncomplicated trauma in the study eye 
within twelve (12) weeks prior to screening. Complicated 
cataract surgery or trauma that may impact access and/or drug 
delivery to the su prachoroidal space is exclusionary.  
21. Hypersensitivity to triamcinolone acetonide, or any of the 
excipi[INVESTIGATOR_680034]® formulation or Oxulumis® device 
components.  
22. Active malignancy or history of malignancy within the past 
five (5) years.  
23. Uncontrolled diabetes with a hemoglobin A1c (HbA1c) 
> 12% or any other uncontrolled systemic disease at 
screening.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 21 of 111 24. Uncontrolled hypertension, defined as blood pressure with a 
systolic value of ≥ 160mmHg or a diastolic value of ≥ [ADDRESS_920150] : Triamcinolone acetonide injectable suspension 40  mg/mL  
(Triesence®) administered with the Oxulumis® ophthalmic  
administration  device to the  suprachoroidal  space . 
The trial will investigate two  dose levels of TA:  
1. Low dose arm: t he target dose of triamcinolone acetonide 
suspension is 2.4 mg ( i.e., 60µl).  
2. Mid dose arm: the target dose of triamcinolone suspension is 
4.0mg ( i.e., 100µl)  
The Oxulumis® is a sterile, semi -automatically operated, minimally 
invasive, single -use device designed to deploy a therapeutic drug via 
a delivery -guiding illuminated ophthalmic microcatheter into the 
suprachoroidal space. The illumination confirms  that the 
microcatheter is deployed  correctly, prior to administration of the 
therapeutic drug.  
Subjects  will receive topi[INVESTIGATOR_680035]/or local injection 
anesthesia  (typi[INVESTIGATOR_680036])  at the discretion of the 
investigator to reduce potential  pain and  discomfort during the 
OXUCT -[ADDRESS_920151] characteristics (e.g., enophthalmos, and/or thick, 
opaque conjunctiva or similar features) suggest an increase d 
complexity for engaging the Oxulumis® insertion needle into the 
sclera, a variant of the Oxulumis® procedure may be used with an 
incision of the conjunctiva /tenon . This procedural variant  is expected 
to be carried out after local injection anesthesia in an operating / 
procedure room.  Locally established procedural practices for 
conjunctival/tenon  incision and closure will be used at the discretion 
of the investigator.  
The treatment visit V2, Day [ADDRESS_920152] attempt of study treatment is made in -clinic  and 
treatment  cannot be administered , a second attempt in an 
operating/procedure room is allowed. Only assessments feasible in an 
operating/procedure room setting need to be performed on this 
treatment day (for details see 1.3)  The maximum time interval from  
starting activities of V2 to completion is [ADDRESS_920153]  be 
applied  before  the Oxulumis® procedure . 
Dosing Regimen:  A single suprachoroidal administration of triamcinolone acetonide 
suspension (Triesence®) (at two differen t dose levels per treatment 
arm, 2.4mg and 4.0mg, respectively)  will be given at the baseline 
visit (Visit 2, Day 0) in the study eye.  
Reference/Comp ar
ator Therapy:  This trial will assess in two  randomized  parallel groups the safety and 
exploratory efficacy of triamcinolone acetonide suspension 40mg/ml  
at dose levels of 2.4mg and 4.0mg.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 23 of 111 Need for Follow -
On Treatment .  
End-of-Study  Subjects will be followed with regular visits (from Week 4 on , at 
monthly intervals) to assess the safety and the course of visual and 
anatomic outcomes.  
From Week [ADDRESS_920154] prespecified 
criteria indicating the need for follow -on treatment ( i.e., indicating 
the end of the current treatment interval). Criteria are as follows:  
• At least [ADDRESS_920155] value since the baseline visit [Visit 2, 
day 0]. 
• A decrease in BCVA of at least [ADDRESS_920156] achieved BCVA since the baseline visit [Visit 2, day 0], 
that in the opi[INVESTIGATOR_871], is due to worsening of 
DME.  
For subjects showing no reduction of edema or no improvement of 
BCVA, the baseline visit will be considered the bes t CST or BCVA 
value.  
If one or both above criteria are met, the subject will be eligible for 
follow -on treatment and will be managed according to the local 
standard of care  after ending participation in this clinical  trial. 
If the investigator decides that the subject requires follow -on 
treatment during a study visit, the respective visit -day procedures will 
be extended to include the assessments foreseen for the EoS visit. 
This visit will then be an early termination/ EoS visit. 
For subjects who decide to discontinue study participation for any 
reason, the respective visit -day procedures will be extended to 
include the assessments scheduled for the EoS visit (or an EoS visit 
will be scheduled for the subject if notification of  discontinuation is 
received outside of a scheduled study visit). This visit will then be an 
early termination/ EoS visit.  
If the non -study eye requires management for ME, this shall  be 
carried out according to the local standard of care . 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 24 of 111 Assessments/Evalu
ations:  Safety : 
• Adverse events (AE) and Adverse Device Effects (ADE) will 
be coded to system organ classes (SOCs) and preferred terms 
(PTs) using the Medical Dictionary for Regulatory Activities 
(MedDRA).  
o Subjects will be monitored for saf ety throughout the study.  
o On the injection day, D ay 0, Visit 2, subjects will be 
monitored for at least sixty (60) minutes immediately 
following the suprachoroidal administration of TA.  
Additional assessments including efficacy endpoints : 
• Best-corrected visual acuity (BCVA) using the ETDRS 
methodology  
• IOP measurement  
• Slit-lamp biomicroscopy  
• Dilated indirect ophthalmoscopy  
• SD-OCT  
• OCT Angiography  (OCT -A) 
• Color fundus photography using (UWF) imaging or  
4 wide -field (4WF) imaging  
• (if available at site:)  Swept -Source (SS) -OCT or 
Ultra -widefield ( UWF ) SD-OCT  
Selection of Study 
Eye: Only one (1) eye will be determined as the study eye and only the 
study eye will receive a single administration of study drug at Visit 2 , 
Day 0 . 
Study eyes need to meet all inclusion criteria and none of the 
exclusion criteria. If both eyes meet the relevant criteria, the eye with 
the worse BCVA will be selected as the study eye; if both eyes meet 
OXUCT -[ADDRESS_920157] s’ fellow eyes may continue to receive non -study treatment 
following guidelines and standards at the investigational site. 
Treatment of the fellow eye is not considered part of the study 
treatment.  
Statistical 
Methods:  Analyses will generally be descriptive in nature . The incidence of 
AEs and ADEs will be summarized for the study population. Ocular 
AEs will be summarized for all subjects using descriptive statistics 
for each eye  and per treatment arm . Efficacy endpoints will be 
summarized for all subjects using descriptive statistics for each eye  
and per treatment arm . Summary statistics for other safety and 
efficacy  outcomes  will be presented. Further details will be provided 
in a Statistical Analysi s Plan (SAP).  Descriptive subgroup analysis 
will be performed and will be defined in a statistical analysis plan 
(SAP).  
OXUCT -103 Clinical Trial Protocol V 3.0 17 Feb 2023  Oxular Limited  
 Confidential  page 26 of 111 
 1.2 Schema  
The study flow diagram is displayed in  Figure 1.  
Figure 1: Study Flow Diagram  
 
⧫ = Suprachoroidal Triamcinolone Administration ; all baseline visit  activities, e.g., a 2nd 
treatment attempt in an operating/procedure room , need to be completed within 14 days , 
Q4W = monthly  

OXUCT -103 Clinical Trial Protocol V 3.0 17 Feb 2023  Oxular Limited  
 Confidential  page 27 of 111 
  
1.3 Schedule of Activities (So A) 
Table [ADDRESS_920158]-Baseline Follow -Up 
Study Visit  1 2 3 4 5 6 7 8 9 10 
Days/Week  Day 
-21 to -2 D0 
To be completed  within 14 days  D1 W1 W4 W8 W12  W16  W20  W24  
ET/EoS  
Visit Window (days) a    
in-clinic b variant with 
conj./tenon 
incision  j + 1 ± 3 ± 5 ± 5 ± 5 ± 5 ± 5 ± 5 
ICF X           
Eligibility  X X* X*         
Randomization   X* Xk         
Demographics  X           
Medical History  X           
Concomitant Medication  X X* X* X X X X X X X X 
AEs and ADE  X X** X** X X X X X X X X 
Height, Weight,  
Vital Signs  X           
Lab Assessment  X           
Pregnancy Test d X X* X* - X X X X X X X 
Slit-lamp BM  OU OU* OUk SE SE SE SE OU SE SE OU 
IOP OU OU*/SE***,i OU*,k/SE** SE SE SE SE OU SE SE OU 
BCVAe, f OU OU* OU*,k SE SE SE SE OU SE SE OU 
Dilated Ophthalmoscopy  OU OU*/SE** OU*,k/ SE** SE SE SE SE OU SE SE OU 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 28 of 111  
AEs = adverse events; ADEs = adverse device effects; BCVA = best corrected visual acuity; BM = biomicroscopy; CFP = color fun dus photography, CMs = concomitant 
medications; EoS = end of study; ET = early termination; ETDRS = Early Treatment Diabetic Retino pathy Study; ICF = informed consent form; OCT -A (Ocular Coherence 
Tomography  Angiography) ; OU = both eyes; SD -OCT  = Spectral -Domain Ocular Coherence Tomography; SE = study eye; Tx = treatment.  (*) Pre -treatment, (**) Post -
Attempt or Post -treatment,  (***) Post Treatment . 
a. Visit dates and visit windows are calculated  for the screening visit from the day of the first procedural attempt and for post baseline visits from the date  of the completed 
study treatment administration. Between the maximum interval from start of activities for Visit 2 and the completion is 14 days including a potential 2nd treatment attempt 
in an operating/procedure room , see also footnote b. and c . Study Visit  1 2 3 4 5 6 7 8 9 10 
Days/Week  Day 
-21 to -2 D0 
To be completed  within 14 days  D1 W1 W4 W8 W12  W16  W20  W24  
ET/EoS  
Visit Window (days) a    
in-clinic b variant with 
conj./tenon 
incision  j + 1 ± 3 ± 5 ± 5 ± 5 ± 5 ± 5 ± [ADDRESS_920159]  OU SE*/SE** SE*,k SE SE SE SE OU SE SE OU 
OCT -A OU       OU   OU 
Swept -Source or  
UWF OCT h OU SE***  SE SE SE SE SE SE SE SE 
Color Fundus Photog.  OU SE** SE*,k SE SE SE SE OU SE SE OU 
Overall Assessment of 
Expected Procedural 
Complexity  X           
Study Medication 
Administration   SE SE         
Procedure  
Documentation and  
Assessment   X** X**         
Subject’s Experience 
Assessmentj  X*** X*** X X X      
Assessment of need for 
follow -on treatment       SE SE SE SE SE SE 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 29 of 111 b. Column  shows the schedule of assessment s for a study treatment carried out in a setting with access to devices for  ophthalmic assessment or imaging . 
c. The treatment  day can be primarily performed  in an operating/procedure room or  be split  between a firs t in-clinic attempt followed by [CONTACT_680061]/procedure room  in case of non -completion of administration of the study treatment in the clinic . If the operating/procedure room is not fully equipped with 
ophthalmic assessment  and imaging devices, this assessment schedule is the minimum to be performed.   
d. Females of childbearing potential only. A urine pregnancy test will be performed at screening.  A pregnancy test  on D0  (urine) shall be negative for the subject to receive 
study treatment. Additional pregnancy tests will be performed at monthly  intervals throughout study participation . 
e. BCVA assessments need to be performed in duplicates for the eyes that should be assesse d at visits.  
f. BCVA eligibility will be assessed at the screening visit.  
g. Axial length measurement to assess the axial dimensions of the eye to support exploratory imaging of the location of the depl oyment of study drug in equipped sites only.  
h. SS-OCT or UWF S D-OCT to visualize the site of deployment  will be obtained at sites in which the equipment is available.  
i. On Day  0, subjects will be monitored for at least sixty (60) minutes immediately following study treatment  with at least 2 IOP measurements . 
j. If the Oxulumis® procedure is attempted first in -clinic and then an other  procedural attempt in an operating/procedure room, th e subject’s experience questionnaire will 
only be completed for the completed procedure, i.e., the procedure  when study drug is administered.  
k. In case the study procedure is only performed in an operating/procedure room setting , the mandatory baseline asses sments would have to be performed  still at the 
investigational site, if not available in the operating/procedure room facility.  This may be done prior to or on the same day of treatment administration. All baseline visit 
activities have to be completed within  [ADDRESS_920160] -103 Clinical Trial Protocol V3.0 15 Feb 2023  Oxular Limited  
 Confidential  page 30 of 111 
 2 Introductio n 
2.1 Study Rationale  
Oxular L imited  is developi[INVESTIGATOR_007] a novel investigational ophthalmic administration device, called 
the Oxulumis®, which can be used for semi -automated microcatheterization of the 
suprachoroidal space.  
The Oxulumis® deploys an integrated, highly flexible, atraumatic 7mm microcatheter in the 
suprachoroidal space through a minimally invasive, short (27G) needle insertion in the area of 
the pars plana . The typi[INVESTIGATOR_680037] 
4--7mm. Through the microcatheter of 7mm length , triamcinolone acetonide suspension 
(Triesence®) can be delivered in proximity to the posterior retina. The soft microcatheter 
incorporate s an illuminated shaft . The illumination  is used  to visualize the catheter and  to 
confirm positioning of the microcatheter  and the atraumatic tip in the posterior region before 
administration of the drug product. Drug delivery is performed as low-volume administration.  
Triamcinolone acetonide suspension (Triesence®) disperses slowly in the suprachoroidal 
space following deployment. It is anticipated that the posterior positioning of the drug will 
reduce diffusion of Triesence® and steroid expos ure of anterior ocular tissues, including the 
ciliary body and the lens , which are  relevant structures for  main adverse effects of ocular 
steroid treatment.  
Another clinical advantage of suprachoroidal administration compared to IVT injections is the 
absen ce of penetration of the vitreous cavity. The risk of IVT bacterial contamination leading 
to e.g., endophthalmitis is expected to be reduced.  
Overall,  a combination of the Oxulumis® with a US FDA approved ophthalmic steroid such 
as triamcinolone acetonide suspension (Triesence®) is expected to have the following 
benefits:  
1. Reduction of the risk of steroid -induced complications and adverse events  
2. Enhanced efficacy of triamcinolone acetonide suspension compared to IVT and other 
forms of steroid delivery due to an expected higher steroid concentration in the 
posterior choroid and retina.  
3. Prolonged efficacy compared to IVT delivery of triamcinolone ac etonide suspension  
4. No penetration of the vitreous cavity with the suprachoroidal administration procedure 
of triamcinolone acetonide suspension  
OXUCT -[ADDRESS_920161] -103 clinical trial as a 24-week  randomized , two-
arm, parallel -Group , single-masked,  clinical trial to evaluate safety and tolerability of two 
dose levels of suprachoroidal triamcinolone acetonide administered with the Oxulumis® 
ophthalmic administration in approximately 20 subjects with diabetic macular edema . 
2.2 Background  
There remains a high unmet need for a safe and efficacious treatment for DME in selected 
patients. Currently approved treatments may neither  show satisfactory  peak  efficacy nor 
sustained improvement of vision (Wilkins et al. , 2021 ; Ehlers et al. 2022 ). In addition, steroid  
treatment -related side effects  occur frequently  and may trigger  additional drug treatments  or 
even ocular surgeries The major treatment challenges are summarized below : 
For DME, registered intravitreal (IVT) anti -VEGF treatments ( e.g., Lucentis® or Eylea®) are 
the current standa rd of care (Ehlers et al. , 2022 ). However, a sizeable proportion of DME 
patients experience s very limited vision gains and short -lived or insufficient edema con trol 
due to additional inflammatory factors contributing to chronic DME (Udaondo et al. , 2021 ; 
Zur, Iglicki, and Loewe nstein , 2019 ). Administration of ocular steroids in DME may result in 
adequate disease control , howeve r current formulations and the ir side effect profile s remain 
challenging . For topi[INVESTIGATOR_680038], treatment effects may not last 
sufficiently long with need for early re -treatment (Shah  et al. , 2020 ; Qi et al. , 2012 ). For both 
subtenon and IVT administration, a high incidence of steroid -related adverse events , such as 
cataract formation and increased intraocu lar pressure (IOP) , substantially complicate 
treatment and thereby [CONTACT_680062] a relevant number  of patients 
(Boyer et al. , 2014 ; Ehlers et al. , 2022 ). 
To overcome these therapeutic challenges, an innovative approach for ophthalmic drug 
admin istration  is needed, whic h has the potential to reduce the rate and extent of 
complications with IVT steroid administration and maximize s the benefit/risk ratio by 
[CONTACT_680063] , local steroid concentrations to control  DME. 
In recent clinical trials assessing a device with a  microinjection needle for suprachoroidal 
steroid  administration , first trends of reducing side effects could be observed (Barakat et al. , 
2021 ; Campochiaro et al. , 2018 ; Yeh et al. , 2020 ). However, the microneedle device typi[INVESTIGATOR_680039]. A more 
posterior administration  of steroids using  an insertion point at 4-7mm post the limbus corneae 
in combinati on with deployment of a 7mm - microcatheter is expected to further reduce the risk 
for IOP increases by [CONTACT_680064]. In 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 32 of 111 addition, by [CONTACT_680065], higher local 
concentrations of steroids in the targeted macular region are expected.  
2.3 Preclinical Testing of the Oxulumis® Ophthalmic Administration Device  
The tissue contact [CONTACT_680066]® was tested per the requirements of ISO  [ZIP_CODE] for 
devices with li mited use (<24 hrs.), and the results of this testing demonstrated 
biocompatibility suitable for transient tissue contact [CONTACT_680067]. All 
testing was conducted in accordance with FDA 21 CFR Part 58 Good Laboratory Practice 
(GLP) Re gulations. The results of testing showed that the patient -contact[CONTACT_680068]® passed all the applicable biocompatibility requirements contained in 
ISO [ADDRESS_920162] resulted in le vels of extracted elements that were 
safe based on their relationship with ICH Q3D guidelines for elemental impurities (parenteral 
route of administration).  
The Oxulumis® has also undergone a battery of testing in acute pig and rabbit studies for the 
purpo se of evaluating the device design with regard to the microcatheter formulation, 
structure , and length. In addition, in these studies, the feasibility of dose volumes and the 
effectiveness of training procedures for ocular disease specialists were evaluate d. The current 
Oxulumis® design has been optimized for safety and efficacy of delivery to the suprachoroidal 
space based on outcomes from these preclinical animal studies.  
2.4 Previous clinical experie nce 
The efficacy and safety of IVT steroids in the manageme nt of DME is well documented.  
In their recent Cochrane review, Rittiphairoj et al. reported findings from 10 clinical trials 
involving 4505 eyes  with DME  of 4348 subjects treated with IVT steroids compared to other 
treatments  (Rittiphairoj et al. , 2020 ).  Despi[INVESTIGATOR_680040]  (VA)  and 
reduction of  ME, the authors concluded that benefits from IVT steroid s should be weighed 
against IOP elevation, the use of IOP‐lowering medication, and in phakic patients, the 
progression of cataracts.  
To overcome these potential side effects (IOP elevation and cataract progression), several 
groups have tried to deliver TA via the suprachoroidal space. By [CONTACT_680069], target tissues associated 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 33 of 111 with these complications ( i.e., lens and anterior segment of the eye) are expected to be 
exposed to lower c oncentrations of steroids  and hence , may be less prone to develop these 
side effects.  
Suprachoroidal drug administration  has been proposed as an approach to ophthalmic drug 
administration  resulting in higher concentrations of medication to target tissues ( i.e., in 
choroid , and retina ) and lower concentration s of medication to anterior segment structures  
(Pearce, Hsu, and Yeh , 2015 ). Although already proposed in the late 1970s by [CONTACT_680070], suprachoroidal drug administration  was only pi[INVESTIGATOR_680041] a 
microsurgical cannula (Olsen et al. , 2006 ) or a hollow microneedle (Patel et al., 2012 ) to 
target the suprachoroidal space. These animal studies in non -human primates and rabbits 
demonstrate d detailed drug distribution following suprachoroidal delivery.  
2.4.1 Diabetic Macular Edema:  
Experience with subtenon TA treatment  
For the subtenon treatment of DME with TA, clinical data are summarized in a review and 
meta -analysis (Qi et al. , 2012 ). 
The review compared IVT administration of TA and subtenon TA injections. Overall, the se 
clinical data demonstrate that both administration methods may initially improve VA and 
reduce  ME. However, the subtenon a dministration of TA in DME has a significantly shorter 
duration, as visual and anatomic benefits already decline at the [ADDRESS_920163] to maximum efficacy, durability, and steroid -induced IOP increases. 
Of note, the subtenon  dose of TA is  generally substantially higher (40  mg, 1.0  mL) compared 
to the IVT administered dose (4.0  mg, 100  µl) (Qamar, Saleem, and Saleem , 2013 ). Also, the 
posterior subtenon administration may have some relevant safety complications like an 
accidental direct injection of TA into the choroidal or retinal circulation, perforation of the 
globe, occlusion of the central retinal artery, cataract formation, orbital fat atrophy, 
strabismus, and conjunctival necrosis.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 34 of 111 Experience with suprachoroidal microneedle TA injections  
Recently, clinical trials  (Wykoff et al., 2018 ; Barakat et al. , 2021 ) investigati ng 
microinjecti on techniques in  the area of  the pars plana, suggested the clinical feasibility of 
suprachoroidal administration  with an acceptable safety profile and meaningful clinical 
efficacy.  
In the HULK trial (Wykoff et al., 2018 ), an open -label, 20 subjects study evaluating the use of 
TA applied to the suprachoroidal space with a microinjector in the management of DME, 
treatment naïve subjects (n=10) had 8.5  ETDRS letters improvement at month  6, while those 
previously treated (n=10) improved only  by 1.1 letters. Ten percent ( 10%) of the subjects 
(n=2 of 20) experienced a ≥ [ADDRESS_920164] progression. Notably, there was injection site pain (1 of 20 subjects) and 
inadvertent IVT drug deposit (1 of 20  subjects).  
In the TYB EE Phase 2 trial, 71 subjects with DME were randomized to receive either : 
i) 4 monthly doses of aflibercept (Day 0, Weeks 4, 8, and 12) with additional as -needed  
aflibercept doses at Weeks 16 and /or 20), or  ii) 2 TA injections (4 mg) administered to the 
suprachoroidal space (Day 0 and week 12) with the option for aflibercept at weeks 4, 8, 16 
and 20  as needed  (Barakat et al. , 2021 ). The primary endpoint was the mean change in BCVA 
from baseline at Week  24. Despi[INVESTIGATOR_680042] (226. 5 µm mean 
change at week  24) for the combination arm compared to the aflibercept mono arm 
(-176.1  µm), the mean change in BCVA at week 24 for the combinat ion arm (12.3  ETDRS 
letters) was not statistically different from the aflibercept arm (13.[ADDRESS_920165], two-sided significance level of 0.10). An IOP increase of more than 30mmHg occurred in 
3 subjects in the active group and 0 subjects in  the control group. Intraocular pressure 
increases of more than 10mmHg occurred in 5 and 0 subjects in the active and control groups, 
respectively (Bara kat et al., 2021 ). 
2.4.2 Suprachoroidal Administration  of TA via Microcathe terization  
There has been rapid and substantial progress in medical technology since Penkov’s 
conceptualization of suprachoroidal drug administration  in the 1960s. This has resulted in the 
technical development and exploration of the feasibility of medical devices that use 
microcatheters to  administer  drugs to the suprachoroidal space.  
For the use of microcatheters to reach the suprachoroidal space, more recent smaller studies 
showed substantial progress of the device technique resulting in therapeutic benefits in 
advanced retinal disease unresponsive to conventional treatments.  

OXUCT -[ADDRESS_920166] 
decade . 
The use of microcathe ter drug administration  to the suprachoroidal space was reported in 
11 subjects (eyes) with advanced neovascular AMD that failed to respond to conventional 
therapy (Chang , 2009 ).  Treatment consisted of a single dose of bevacizumab (Avastin) and/or 
TA administered by [CONTACT_680071]. The average preope rative BCVA was 
1.78 ± 0.41 logMAR  units, which increased to 1.40  ± 0.60 at three months and was 
1.63 ± 0.71 at 12 months. Overall, BCVA showed a trend towards improvement but in this 
small group of subjects did not reach statistical significance. After th ree months, the BCVA 
appeared to regress towards preoperative levels. The average central subfield foveal thickness 
appeared to decrease after surgery at all time points. Total macular volume significantly 
decreased from baseline levels at six months. Only  two of 11 eyes had an elevation of IOP 
above 21  mmHg at any postoperative visit beyond one week, with both eyes reaching an IOP 
of 24  mmHg and resolving  without treatment. Of the six eyes that were phakic at baseline, 
one eye with a pre-existing grade 2+ nuclear sclerotic cataract developed a 1+ posterior 
subcapsular cataract during the follow -up period.  
Tetz and co -workers (Tetz, Rizzo, and Augustin , 2012 ) investigated the suprachoroidal 
administration of a combination of bevacizumab and TA to the  submacular  suprachoroidal 
space, via a microcatheter, in eyes with advanced neovascular AMD that failed to respond to 
conventional therapy. A slight improvement i n the average BCVA at one month and six 
months was  observed, but  statistical significance  was not reached at any time point  compared 
with baseline.   Initial CSFT was 407.2  μm (SD=229.8), decreasing at one month to 
333.3  μm (SD=179.4), remaining stable at t hree months and trending  towards initial levels at 
six months (384.8  μm, SD=265.7).  No serious complications  were encountered during the 
administration of therapy.   Only one  of 21  eyes included in the study  experienced  a transient 
elevation in IOP at three  months, which was medically controlled. In  two eyes,  an increase in 
nuclear sclerotic cataracts  was noted.  
Rizzo and  co-workers (Rizzo et al. , 2012 ) evaluated [ADDRESS_920167] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 36 of 111 BCVA improved by 2+ lines in [ADDRESS_920168] completely resolved in all eyes.  There were no complications  
observed . 
In compassionate use cases in Switzerland, as of December  2021, Oxulumis® was used to 
deliver Triesence® in a total of 4 patients with 6 treatments (2 repeat treatments of the initially 
treated eye) with refractory ME of different etiologies (post -surgical ME, and non-infectious 
inflammatory cystoi d ME). In contrast to their pre -treatment, these patients showed , after 
suprachoroidal administration of TA , a robust anatomical response with a quick onset, as well 
as visual improvements. No device -related AEs were described and no challenges with IOP 
rises after TA administration  were encountered . 
Compared to the administration of TA using a micro needle  device at the pars plana, 
Oxulumis® is specifically designed to administer  the drug via microcatheterization more 
posteriorly, potentially allowing for effective, higher concentrations of drug in the macular 
region and lower exposure of the anterior segment tissues to TA. This is expected to translate 
into better benefit/risk ba sed on greater efficacy and a better safety profile for  triamcinolone 
acetonide suspension  (Triesence®) delivered to the suprachoroidal space using the Oxulumis®. 
2.5 Benefit/Risk Assessment  
To date, only a limited number of patients with ME have been treated with Triesence® 
administered with the Oxulumis®, limiting the ability to establish a robust benefit/risk profile. 
However, so far, no severe, serious adverse events or serious adverse device effects have  been 
reported.  
Suprachoroidal administration of triamcinolone acetonide suspension with Oxulumis®, in 
contrast to IVT injection, does not penetrate the vitreous cavity, and reaches more posterior 
sections of the retina, towards the macula, through the suprachoroidal spac e. The 
suprachoroidal route of administration is, therefore, expected to result in improved safety and 
tolerability, particularly with regard to complications, such as increased IOP in addition to 
potential improvement in efficacy due to the expected highe r concentration of triamcinolone 
acetonide suspension in the retina and choroid. For repeat treatments over a longer period of 
time, the cataract risk would be expected to be smaller, although the duration of the current 
clinical trial with a single admini stration and follow -up of up to [ADDRESS_920169] progression in DME (TYBEE 
trial) and ME due to non -infectious uveitis  (PEACHTREE trial) (Price, Albini, and Yeh , 
2020 ; Barakat et al. , 2021 ).  
The combination of the Oxulumis® plus triamcinolone acetonide suspension  (Triesence®) 
used in the current trial is expected to satisfy an unmet medical need to:  
1. Reduce the risk of steroid -induced complications and adverse events  
2. Enhance the efficacy of triamcinolone acetonide suspension  compared to IVT 
administration  
3. Prolong  the efficacy of triamcinolone acetonide suspension  compared to IVT 
administration  
4. Ensure n on-penetration of the vitreous cavi ty with the suprachoroidal 
administration . 
Theoretical class risks associated with the suprachoroidal administration procedure include: 
endophthalmitis, choroidal hemorrhages , choroidal effusion, retinal penetration, and retinal 
detachment, amongst others. In addition, the eligibility criteria of this trial exclude subjects 
with structural lesions of the eyewall (e.g., subjects with scleral ectasia or scleral defect , 
which may have a risk of scleral perforation ) to further reduce  any potential procedural risks. 
The atraumatic design, a tangential  angle of approach for device  insertion (not perpendicular 
to the sclera  once the sclera is reached in the insertion phase  and not pointing to the vitreous 
cavity), and the 7mm length of the microcatheter, together with the rounded ball -like catheter  
tip, as well as control over the speed of the microcatheter deployment  by [CONTACT_680072]® are design elements expected to prevent or substantially limit the risk of the 
adverse events summarized above.  Still, as the Oxulumis® procedure is relatively novel , non -
completion of microcatheter placement may happen in an in -clinic setting, requiring the use of 
a procedural variant that uses an incision of the conjunctiva  and/or tenon  to increase visibility 
of the scleral engagement in the insertion phase of the Oxulumis® procedure.  
To optimize detection of any adverse events and other unforeseen risks and to potentially 
initiate countermeasures in a timely fashion, subject s will be monitored closely for at least 
60 minutes after administration of triamcinolone acetonide suspension ( Triesence®) to the 
suprachoroidal space. This monitoring includes an ophthal moscopy , IOP measurements , and 
post-treatment retinal imaging . Additionally, visits following treatment, on day 1, week 1, 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 38 of 111 week 4, and every 4 weeks thereafter, will include multiple safety evaluations to ensure the 
detection and management of any emerging  adverse events.  
3 Objectives  and Endpoint s 
3.1 Objectives  
The objectives of this exploratory  clinical trial are summarized in detail below.  
3.1.1 Primary Objective  
• To evaluate the safety and tolerability of two dose levels of triamcinolone acetonide 
administered with the Oxulumis® to the suprachoroidal space in subjects with DME.  
3.1.2 Explorative Objective  
• To explore the efficacy of two dose levels of triamcinolone acetonide with respect to VA 
changes, edema control, and durability of the treatment effect of suprachoroidal 
triamcinolone acetonide suspension (Triesence®) in subjects with DME.  
3.2 Endpoints  
3.2.1 Primary (Safety ) Endpoints  
The primary endpoint of this study is safety and tolerability as assessed by:  
1. Frequency of ocular and systemic adverse events (treatment -emergent serious adverse 
events [SAEs] and treatment -emergent non -serious adverse events [TEAEs])  
2. Frequency of adverse device effects (ADEs, serious ADEs [SADEs])  
3.2.2 Exploratory Efficacy (and/or Safety ) Endpoints  
1. Mean Change in BCVA (ETDRS) at all study visits through Week [ADDRESS_920170] 15 letters at all study visits through Week 24 compared to baseline.  
3. Time to subjects meeting criteria for follow -on treatment (per pre -specified criteria).  
4. Mean Change in Central subfield thickness (CST) at study visits through Week [ADDRESS_920171] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 39 of 111 4 Clinical Trial  Design  
4.1 Overall Trial Design  
This is a  24-week , randomized , two -arm, parallel -group, single -masked,  clinical trial to 
evaluate  safety and tolerability of two dose levels of suprachoroidal triamcinolone acetonide 
administered with the Oxulumis® ophthalmic administration in 20 subjects with DME .  
Triamcinolone acetonide suspension ( Triesence®) will be administered  to the suprachoroidal 
space in subjects with DME showing short -lived, limited , or no response to prior  anti-VEGF 
or steroid  therap y. 
A focus of this trial is to evaluate the feasibility , safety, and tolerability of the ophthalmic 
administration of a low a nd a mid -dose of suprachoroidal triamcinolone acetonide suspension 
(Triesence®) with the Oxulumis® in DME. In addition, for the two dose groups of the trial, 
efficacy data on visual and anatomic changes will be collected.  
To support the main objectives of this trial, a sample size of [ADDRESS_920172] to s afety 
considerations including initial safety and feasibility experience with suprachoroidal 
administration procedure.  
After a screening period, approximately 20 eligible DME subjects will be randomized using a 
1:1 ratio to receive a single administration of one of two dose levels of TA (low dose, 2.4mg. 
or mid -dose, 4.0mg, respectively).  Subjects in whom the  study  treatment cannot be 
administered will be replaced.  Randomization will limit bias in assignment to one of the two 
dose levels . 
The study will be conducted by [CONTACT_680073][INVESTIGATOR_680043] 10 investigational sites.  
Table 2 Treatment groups of two dose levels of triamcinolone acetonide suspension  
Treatment 
Arm Interventio n Subjects  
1 One treatment with suprachoroidal low dose (2.4mg ) 
triamcinolone acetonide  N=10  
2 One treatment with suprachoroidal mid-dose (4.0mg ) 
triamcinolone acetonide  N=[ADDRESS_920173] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 40 of 111 Clinical visits will occur on Screening Day, Day 0, Day 1, Week 1, Week 4, and then every 
four (4)  weeks thereafter for a total of twenty -four (24) weeks. From Week [ADDRESS_920174] attempt 
of study treatment is made in -clinic  and treatment cannot be administered , a second attempt in 
an operating/procedure room  is allowed. Only assessments feasible in an operating/procedure 
room setting need to be performed for this 2nd treatment attempt  (for details see 1.3). The 
maximum time interval from starting activities of V2 to completion is 14  days.  If the 
investigator decides to perform the Oxulumis procedure directly in an operating/procedure 
room, some assessments , as indicated in Section 1.3, need to be performed before the 
administration of study treatment.  The follow -up period after a completed treatment 
administration will be up to twenty -four (24) weeks.  
If subjects show a need for the next treatment of DME according to pre -specified criteria (for 
details see  Section  6.1.8 ), participation in this clinical investigation will end, and an early 
termination/end of the study visit will be conducted at the respective visit date. In this case, 
the follow -up period will be shorter than 24 weeks.  
For subjects who decide to discontinue study participation for any reason, the respective visit -
day procedures will be extended to include the assessments scheduled for the EoS visit (or an 
EoS visit will be scheduled for the subject if notification of dis continuation is received outside 
of a scheduled study visit). For subjects in whom the treatment administration could not be 
completed on the respective treatment day (s), only a CFP and a SD -OCT need to be acquired . 
This visit will then be an early termina tion/end -of-study visit.  
After completion of participation in this clinical trial, patients will continue treatment with 
therapeutic options determined by [CONTACT_680074].  
Periodica lly, the coordinating investigator [INVESTIGATOR_680044], continue with changes, or be terminated.  
Study eyes  shall  meet all inclusion criteria and none of the exclusion criteria. If both eyes 
meet the relevant criteria, the eye with the worse BCVA will be selected as the study eye; if 
both eyes meet the relevant criteria and have the same BCVA, the investigator can select the 
study eye.  

OXUCT -[ADDRESS_920175] s’ fellow eyes may continue to receive non -study treatment following guidelines and 
standards at the investigational site. Treatment of the fellow eye is not considered a study 
treatment.  If the non -study eye requires manag ement for DME, this should be carried out 
according to the local standards of care. Treatment of non -study eyes is not considered a study 
treatment.  
4.[ADDRESS_920176] -103 exploratory  clinical trial will evaluate safety, tolerability, and the efficacy 
of administering Triesence® (2.4 mg) to the suprachoroidal space using the Oxulumis® in 
subjects with DME with short -lived, limited or no therapeutic response  with prior therapy 
with ocul ar injections of steroids and/ or anti -VEGF agents . For details on the eligibility 
criteria see Section 5.1 and Section 5.2. 
4.3 Justification of Dose  
The current trial  evaluates two different dose levels. The low dose is 2.4mg TA (60µl of a 
40mg/ml TA suspension). The mid dose is 4.0mg TA (100µl of a 40mg/ml TA suspension).  
In a compassionate use program in Switzerland, both dose levels , 2.4mg and 4.0mg , were 
applied in patients with cystoid macular edema (CME) or post -surgical inflammatory edema 
refractory to standard treatments.  
The current trial OXUCT -[ADDRESS_920177] dose for IVT injection is 4.0mg. This dose level will be administered in the 
current trial in the mid dose group. In addition, 2.4mg TA will be used in the low dose group, 
Using the Oxulumis® device i n both  treatment  groups, TA is expected to be administered 
closer to the location of the disease activity compared to other treatment approaches. Local 
concentrations of TA in the retinal tissues are expected to be higher compared to the same 
doses administered by [CONTACT_680075].  

OXUCT -[ADDRESS_920178] either : 
• Received the study drug and have been followed for 24 weeks ; or  
• Met criteria for follow -on treatment, or  
• Have withdrawn c onsent , or 
• Are lost to follow -up 
A subject  is considered to have completed the study if the subject  has received the study drug  
and has completed  the 8 study visits over the 2 4-week follow -up perio d, which includes the 
final EoS visit . 
5 Study Population  
5.1 Inclusion Criteria  
Subjects will be eligible if they meet all the following  inclusion criteria:  
1. Able to understand and sign an informed consent form.  
2. At least [ADDRESS_920179] DME involving the center of the fovea in the study eye with central subfield 
thickness (CST) on SD -OCT of:  
≥ 320 for males or ≥ 305 for females on Spectralis (Heidelberg) or  
≥ 305 for males or ≥ 290 for females with Cirrus (Zeiss).  
5. Have BCVA in the study eye of ≤73 ETDRS letters (approximate Snellen equivalent of 
20/40 or worse) at the screening visit. The eligibility will be assessed based on the 
ETDRS BCVA letter score.  
6. Short -lived, limited, or no response to prior ocular injection t herapy ( e.g., IVT or 
subtenon) of steroids and/or anti -VEGF agents based on the investigator’s assessment. 
Short -lived in this trial is defined as less than 4 weeks.  
7. For women who are not postmenopausal ( i.e., at least12 months of non -therapy -
induced am enorrhea or surgically sterile (absence of ovaries and/or uterus) agreement 
to remain abstinent or use combined contraceptive methods that result in a failure rate 
of less than 1% per year from the treatment visit (Day 0) until the end of trial 
participati on, or for at least 12 weeks from the treatment  visit (Day 0), if study 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 43 of 111 participation ends before visit 7, Week 12. Examples of contraceptive methods with an 
expected failure rate of less than 1% per year include male sterilization, hormonal 
implants, pro per use of combined oral or injected hormonal contraceptives, and certain 
intrauterine devices. Alternatively, two methods ( e.g., two barrier methods such as a 
condom and a cervical cap) may be combined to achieve a failure rate of less than 1% 
per year;  barrier methods must always be supplemented with the use of a spermicide.  
8. Males must agree to use a barrier method of contraception from the treatment visit 
(Day 0) until the end of trial participation, or for at least 12 weeks from the treatment 
visit ( Day 0), if study participation ends before visit 7, Week 12.  
9. Subject must be willing not to participate in any other clinical trial including an 
investigational medicinal product (IMP) or an investigational device until the end of 
the participation in t his trial.  
5.2 Exclusion Criteria  
Subjects will be eligible if they do not meet any of the following  exclusion criteria:  
1. Presence of any significant ocular or non -ocular disease/disorder (or medication and/or 
laboratory test abnormalities) which, in the opi[INVESTIGATOR_680045], may either put the subject at risk because 
of participation in the trial, may influence the results of the trial, or the subject’s 
ability to participate in the trial.  
2. Macular edema considered due to a cause othe r than diabetes mellitus in the study eye.  
3. Condition, in the study eye, in which visual acuity is not expected to improve from the 
resolution of macular edema ( e.g., foveal atrophy, clinically relevant loss of ellipsoid 
zone, pi[INVESTIGATOR_396536], vitreom acular traction, or nonretinal causes) . 
4. Conditions, in the study eye, that may render the suprachoroidal microcatheter 
insertion and deployment difficult or subject the patient to excessive risk of 
complications. Examples include but are not limited to ocular surface diseases  with 
signi ficant conjunctival edema and/or inflammation , ocular hypotony, scleral 
staphylomas, necrotizing scleritis, scleral melting, excessive choroidal scarring e.g., 
associated with pan -retinal photocoagulation, amongst others.  
5. Macular laser photocoagulation or panretinal laser photocoagulation (PRP) in the 
study eye performed within sixteen (16) weeks prior to screening.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 44 of 111 6. Active proliferative diabetic retinopathy (PDR) or sequelae of PDR (including iris 
neovascularization, vitreous hemorrhage, tractional retinal detachment, extensive 
scarring following PRP) at screening in the study eye.  
7. History of recurrent or active intraocular inflammation in either eye ( e.g., uveitis) 
within 12 weeks prior to screening.  
8. Infectious eye disease s like infectious blepharitis, keratitis, or conjunctivitis in either 
eye within four (4) weeks of screening.  
9. IOP ≥ 22 mmHg, or glaucomatous disc changes ( i.e., a cup disc ratio greater than 0.8) 
in the study eye at screening.  
10. History of glaucoma surgery, and or anti -glaucoma therapy with more than two active 
substances (in separate or a combination preparation) at the s creening visit are  
exclusionary.  
11. History of closed -angle glaucoma.  
12. IOP <6mmHg (hypotony) in the study eye at screening.  
13. Spherical equivalent of the refractive error of −6 diopters of myopia or worse (prior to 
cataract or refractive surgery) at screening.  
14. Cataract or other media opacity that limits the ability to obtain the planned imaging 
assessments.  
15. History of retinal detachment.  
16. Subjects who were previously treated for DME in the study eye must not have 
received:  
a.) an intravitreal anti -VEGF treatment within four (4) weeks before screening. The 4-
week interval before screening is used for IVT bevacizumab, ranibizumab, 
aflibercept, br olucizumab, or faricimab ( i.e., a combined Anti -VEGF/anti -Ang2 
agent), as also inclusion criterion No. [ADDRESS_920180] be met.  
b.) Prior treatment with SUSVIMO® (Port Delivery System ) implant at any time is 
exclusionary.  
c.) Intra - or periocular/sub tenon triamcinolone acetonide suspension  within 12 weeks 
before screening.  
d.) Intravitreal dexamethasone implant  (Ozurdex®) within [ADDRESS_920181] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 45 of 111 e.) Prior treatment with longer duration implants ( e.g., fluocinolone acetonide IVT 
implant , e.g., Iluvien®) at any time is exclusionary.  
f.) Prior treatment with suprachoroidal steroids  (commercial, investigational, or off -
label) at any time is exclusionary.  
17. Concurrent use of systemic glucocorticoid medications or systemic steroids within 
twelve (12) week s before screening is exclusionary.  
Intranasal, inhaled, and extra -ocular topi[INVESTIGATOR_88900].  
18. Treatment with ocriplasmin (Jetrea®) at any time.  
19. History of vitreoretinal surgery (including surgery for retinal detachment or scleral 
buckle) i n the study eye. Vitrectomy is only exclusionary, if within [ADDRESS_920182] surgery, or 
uncomplicated trauma in the study eye within twelve (12) weeks prior to screening. 
Complica ted cataract surgery or trauma that may impact access and/or drug delivery to 
the suprachoroidal space are exclusionary.  
21. Hypersensitivity to triamcinolone acetonide, or any of the excipi[INVESTIGATOR_680034]® 
formulation or Oxulumis® device components.  
22. Active malignancy or history of malignancy within the past five (5) years.  
23. Uncontrolled diabetes with a hemoglobin A1c (HbA1c) > 12% or any other 
uncontrolled systemic disease at screening.  
24. Uncontrolled hypertension, defined as blood pressure with a systolic value of ≥ 
160mmHg or a diastolic value of ≥ [ADDRESS_920183] s to m eet the CONSORT publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in  this study (screen failure) may be 
rescreened once after failing the initial screening. The rescreening can occur at any time after 
the reason for screen failure is addressed. Rescreened subject s shall be assigned a new subject  
number and sign a new ICF f or each screening/rescreening event.  
[ADDRESS_920184] -103 clinical trial,  Triesence® will be administered with the Oxulumis® 
Ophthalmic Administration Device to the suprachoroidal spa ce of study eyes.  
6.1.1 Oxulumis® Ophthalmic Administration Device  
The Oxulumis® ophthalmic administration device is a sterile, semi -automatically operated, 
minimally invasive, single -use device. It is designed to deploy a  therapeutic drug via 
a delivery -guiding  illuminated ophthalmic microcatheter to ophthalmic compartments, e.g., to 
the suprachoroidal space. The illumination provides confirmation t hat the microcatheter is 
inserted and deployed correctly, prior to administration of the therapeutic drug. With a 27G 
insertion needle and an 7mm microcatheter, the Oxulumis® administration device is well 
suited to administer suspension s of drugs like Trie sence® to the posterior retina.  
For the Oxulumis® administration procedure, subjects may receive topi[INVESTIGATOR_12866] ( e.g., 
anesthetic eye drops, gels, local subconjunctival, or anesthetic injections , typi[INVESTIGATOR_680046] ) to reduce potential  pain and discomfort during the procedure.  
As for  IVT injections, antiseptic conditions shall  be applied following the standard procedures 
at the investigational site. Colorless disinfectants for ophthalmic use, e.g., chlorhexidine or 
application of PVP io dine followed by [CONTACT_680076], are recommended. Details 
about the Oxulumis® device and the ophthalmic administration are available in the Instruction 
for Use (IFU) manual.  
The materials used in the Oxulumis® were selected for appropriate mechanical properties, 
optical properties, and biocompatibility of the tissue and fluid contact [CONTACT_489742].  The tissue 
OXUCT -[ADDRESS_920185] contact[CONTACT_680077]® have been tested to ISO [ADDRESS_920186] contact[CONTACT_680078]:  
 
6.1.2 Triamcinolone acetonide (Triesence®) 
Triesence® (Triamcinolone acetonide  [TA]  40 mg/mL; [COMPANY_001]  Pharmaceutical Corporation 
[former subsidiary: Alcon Laboratories, Inc. ]) is a synthetic corticosteroid with anti -
inflammatory action approved by [CONTACT_6581] (US FDA) 
for IVT administration for the treatment of ophthalmic diseases including sympathetic 
ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unrespo nsive to 
topi[INVESTIGATOR_11930]. The suprachoroidal microcatheterization with the Oxulumis® is an 
investigational route of administration for Triesence®. In the context of other development 
programs, clinical data on the general ly favorable safety of  other forms of  suprachoroidal 
admini stration of TA have been generated (see  Section 2.4.2 ). 
Hypersensitivity reactions may occur to triamcinolone acetonide  or any of the excipi[INVESTIGATOR_680047]® formulation . Per the US prescribing information  of Triesence®, each mL of the 
sterile, aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride 
for isotonicity, 0.5% (w/v) carboxymethylcellulose sodium and 0.015% polysorbate 80. It also 
contains potassium chloride, calcium chl oride (dihydrate), magnesium chloride (hexahydrate), 
sodium acetate (trihydrate), sodium citrate (dihydrate) and water for injection. Sodium 
hydroxide and hydrochloric acid may be present to adjust pH to a target value 6 – 7.5. 
6.1.[ADDRESS_920187] confirm appropriate conditions ( e.g., temperature) 
have been maintained during transit for all study intervention s received, and any 
discrepancies are reported and resolved before use of the study intervention.  
2. Only subject s enrolled in the study may receive study intervention, and only 
authorized site staff may supply, prepare, or administer study intervention.  
3. All study intervention s must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  

OXUCT -[ADDRESS_920188] maintenance ( i.e., receipt, reconciliation, and final disposition records).  
5. Unused products are accounted for and returned to the Sponsor or their designee for 
destruction or destr oyed locally upon agreement with and approval from the sponsor 
or their designee.  
6.1.4 Assignment to Study Intervention  
This is a double -arm study in which all enrolled subjects will be randomized  at a 1:1 ratio  to 
receive either low (2.4mg) or mid (4mg) dose o f TA in a single -masked manner . Accordingly,  
approximately 10 subjects will be treated at each of the two dose levels.  A central 
randomization scheme provided by [CONTACT_161467] (IVRS)/interactive 
web response system (IWRS) to the desi gnated study pharmacist (or qualified designee).  If 
subjects are randomized but the study treatment cannot be administered , these subjects will be 
replaced , targeting approximately [ADDRESS_920189] on 
masking is expected from the potential repeat of procedural attempts in an 
operating/procedure room. In case of any emergency, the treating site investigator can share 
the dose level upon request and needs to document all details regarding this procedure.  
6.1.[ADDRESS_920190]’s masking .  
6.1.7 Dose Modification  
There is no planned dose modification in this study.  
6.1.8 Follow -on Treatment  
Subjects will be followed with regular v isits (from Week 4 on with monthly intervals) to 
assess the safety and the course of visual and anatomic outcomes. From Week [ADDRESS_920191] prespecified criteria indicating the need for follow -on treatment ( i.e., 
indicating the en d of the current treatment interval).  
Criteria are as follows:  
• At least [ADDRESS_920192] 
value since the baseline visit [Visit 2, day  0]. 
• A decrease in BCVA of at least [ADDRESS_920193] achieved BCVA 
since the baseline visit [Visit 2, day 0], that in the opi[INVESTIGATOR_871], is due 
to worsening of DME.  
For subjects showing no reduction of edema or no improvement of BCVA, the baseline visit 
will be considered the best CST or BCVA v alue. 
If one or both of the  above criteria are met, the subject will be eligible for follow -on treatment 
and will be managed according to local standard of care.  
If subjects meet the criteria for follow -on treatment in the study, the visit will be considered 
EoS visit, and the assessment scheduled for EoS visit will be performed.  
If the non -study eye requires management for DME, this should be carried out according to 
the local standard of care.  Treatment of non -study eyes is not considered a study treatment.  
6.1.[ADDRESS_920194]  may receive  other  treatment for complications of the underlying diseases  at any 
time if they experience  any complications other than recurrence or progression of ME that 
require  urgent management (e.g., progression to high -risk PDR , intraocular lens replacement 
for visually significant cataract, neovascularization , etc.). 
Any ocular or systemic treatments already clinically indicated or planned  at the time of patient 
referral to this study , should be performed before further consideration of study participation . 
After such treatments, the post intervention intervals defined in the exclusion criteria must be 
met to consider participation or rescr eening, respectively.  The date and time of medication 
administered to treat complications as  well as the name [CONTACT_680109] . If the treatment administered has an effect on DME , e.g., intravitreal anti -
VEGF injection s, the study participation  for this subject ends with the visit, where the 
decision on the need for the treatment of a complication has been recorded and an early 
termination/end -of-study visit will be performed.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 50 of 111 6.1.10  Continued Access to Study Intervention afte r the End of the Study  
There will be no continued access to the study intervention , specifically not to the 
investigational Oxulumis® ophthalmic administration device after the end of the study.  
6.1.[ADDRESS_920195] ( ADE ). In the event  of an accidental  overdose of triamcinolone acetonide suspension 
(Triesence®), subject s will be monitored closely for the emergence of side effects such as 
increased IOP and cataract formation. Any emerging side effects will be managed based on 
the clinical discretion of the investigator and consultation with the sponsor.  
6.2 Prior and Concomitant Therapy  
6.2.1 Permitted Medications and/or Treatments  
Any treatment that the subject receives at the time of enrollment or receives during the 
investigation shall be recorded along with:  
• Reason for use  
• Dates of administration including start and stop  dates  
• Start and stop dates for changes in medications and changes in dose  
• Dosage information including dose and frequency  
Intranasal, inhaled, and topi[INVESTIGATOR_680048]. For further guidance see also Table 3. 
The medical monitor shall be contact[CONTACT_63193].  
6.2.2 Prohibited Medications and/or Treatments  
Subjects should not receive any medications (approved or investigational) for their DME in 
the study eye other than the study drug administered with the Oxulumis® prior to screening  
(see the exclusion criteria in Section 5.2 or during  the trial  as specified in Table 3 in this 
section . This includes medications for DME administered locally ( e.g., IVT,  suprachoroidal,  
topi[INVESTIGATOR_2855], juxtascleral , or periorbital routes) . 
If the investigator determines  that any of these treatments is needed  because of worsening of 
DME, based on follow -on criteria i ns Section 6.1.[ADDRESS_920196] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 51 of 111 visit-day will be extended to include the assessments mandatory for an EoS visit. This visit 
will then be an early termination/end -of-study visit.  
The treatments in Table [ADDRESS_920197] not eligible for this study and are considered a 
“follow -on” treatment triggering the end of study participation when intended to be 
administered to a subject participating in this trial . 
Table 3 Time Intervals of ME Medication before Screening and Qualification as 
Follow -on Treatment  
Therapy  Forbidden interval 
before screening  Qualifies as Follow -on 
Treatment  
Ranibizumab or bevacizumab (IVT)   4 weeks  Yes 
Aflibercept (IVT)   4 weeks  Yes 
Faricimab or brolucizumab (IVT)   4 weeks  Yes 
Intra - or periocular/subtenon 
injection of triamcinolone acetonide   12 weeks  Yes 
IVT dexamethasone implant 
(Ozurdex®)   24 weeks  Yes 
IVT fluocinolone implant  At any time  Yes 
IVT Port Delivery System  At any time  Yes 
Suprachoroidal Steroids  At any time  Yes 
Vitrectomy   12 weeks  Yes 
Focal (Macular) Laser 
Photocoagulation   16 weeks  Yes 
Panretinal Laser Photocoagulation 
(PRP)   16 weeks  Yes 
Investigational Therapi[INVESTIGATOR_680049] 
(agents with anti -VEGF activity, or 
combined pharmacologic activity, 
gene therapi[INVESTIGATOR_014], cell therapi[INVESTIGATOR_014], or any 
other therapeutic medicinal product)  At any time  Yes 
6.2.3 Concomitant Medications  
For previous and concomitant medications, the original terms will be recorded on the Study 
Subjects’ eCRF by [CONTACT_093]. Previous and concomitant medications will not be co ded, 
and verbatim original terms recorded on the eCRF will be presented as data listings.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 52 of 111 6.3 COVID -Related Me asures  
Appropriate precautions to limit the spread of COVID -19, in accordance with the 
investigational site’s standard procedures, should be taken.  
The US FDA guidance on the management of clinical trials during the COVID -19 pandemic  
(FDA Guidance on Conduct of C linical Trials of Medical Products During the COVID -[ADDRESS_920198] 2021 ) will be implemented in this study as applicable. A 
more limited impact on treatment is expected as this clinical trial evaluates a single 
suprachoroidal administra tion of TA in ME. The following measures will be taken:  
• Assessment of feasibility of starting the clinical trial at the chosen sites in close 
collaboration with the sites and factoring in potential risk with repeat travel to the sites 
for study visits.  
• As this clinical trial was designed during the ongoing pandemic, no design changes 
related to the COVID -19 pandemic are expected, but a periodic risk assessment may 
result in adaptations necessitating an amendment.  
• If restrictions would not allow travel of tr eated subject s to the investigation site, safety 
follow -ups could be performed by a local ophthalmologist.  
[ADDRESS_920199]  
Discontinuation/Withdrawal  
7.[ADDRESS_920200] data. If any important safety 
concerns  (e.g., SAEs, SADE, AESIs)  arise, dosing of further subjects could be temporarily 
halted or stopped. If further dosing is stopped, study visits  of enrolled subjects  with e.g., 
follow -up visits including safety evaluations will still be performed as foreseen. If t he 
Sponsor, Medical Monitor or designee, study center monitor, or appropriate regulatory 
officials discover conditions arising during the trial that indicate that the study should be 
halted, this action may be taken after appropriate consultation.  
In addit ion, both the Sponsor and the Investigator reserve the right to terminate the study 
according to the study contract. The Sponsor will timely notify the US FDA and respective 
IRB following applicable  regulations, e.g., 21 CFR 312.56(d) (drugs); 21 CFR 812.1 50 
(devices), and other regulatory authorities as applicable in writing of the trial’s early 
termination.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 53 of 111 Study termination and follow -up will be performed in compliance with the conditions set 
forth in the International Conference on Harmoni zation (ICH) g uidelines (ICHE6 R2), and 
local regulatory requirements.  
7.2 Discontinuation of Study Intervention  
Discontinuation of the study intervention is not foreseen, as this is a one -time ophthalmic 
administration 2.4 mg or 4mg dose of Triesence® to the suprachoroidal  space at the baseline 
visit. See Section 7.[ADDRESS_920201]  Discontinuation/Withdrawal from the Study  
Each subject should remain in the clinical trial until completion of the requ ired follow -up 
period; however, a subject’s participation in the trial may be discontinued at any time. Should 
this occur, the reason for discontinuation shall be documented in the withdrawal form.  
Reasons for discontinuation include the inability to admin ister trial medication with the 
Oxulumis® device . 
Subjects shall be informed about their right to withdraw from the trial at any time and for any 
reason without sanction, penalty, or loss of benefits to which the subject is otherwise entitled. 
Withdrawal from the clinical trial will not jeopardize the subject’s future medical care or 
relationship with the investigator.  
Subjects will be asked to specify the reason for the termination but have the right not to 
answer.  In this case, only potentiall y ongoing adverse events or adverse device defects will be 
followed -up, if the subject agrees.  
The investigator may decide to withdraw a subject from the study at any time with reasonable 
rationale, e.g., lack of improvement or  clinically meaningful  deteri oration of DME after 
administration of Triesence® with the Oxulumis® device.  
The subject’s future care will not be influenced by a decision, voluntary or otherwise, to 
withdraw from the study. All reasonable efforts should be made to retain the subject in the 
clinical trial until the completion of the trial.  
Reasons for the subject’s withdrawal include, but are not limited to:  
• Subject refuses to continue participating in the trial  
• Subject’s non -compliance  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 54 of 111 • Subject’s participation is terminated by [CONTACT_978] [INVESTIGATOR_115655], although the subject 
consented since participation is no longer medically appropriate  
• Subject is ‘lost to follow up ’ (for details  see Section 7.4). 
If a subject withdraws from the clinical trial, the site will record the subject’s reasons for 
withdrawal on a Withdrawal Case Report Form ( CRF ). When subject withdrawal from the 
clinical trial is due to an adverse event the subject will be followed until resolution of that 
adverse event or determination that the subject’s condition is stable for a maximum duration 
of six (6) months. The status of the subject’s condition should be documented at the time of 
withdrawal.  
7.[ADDRESS_920202] is consider ed “lost -to-follow -up” if the subject does not adhere to the scheduled 
follow -up visits but has not explicitly requested to be withdrawn from the clinical trial (this 
does not apply to missed visits). Site personnel should at all times make all reasonable efforts 
to locate and communicate with the subject in order to achieve subject compliance to the 
scheduled follow up visits:  
1. A subject will be considered ‘Lost to Follow Up’ after a minimum of two phone calls 
of a physician or delegate at the investigatio nal site to the subject or contact. These 
two phone calls need to be documented in the subject’s records.  
2. If these attempts are unsuccessful, a letter should be sent to the subject’s last known 
address or general practitioner and a copy of this letter shou ld be maintained in the 
subject’s records.  
Note: If a subject misses one or more of the scheduled follow -up visits (inclusive of the 
assigned visit windows), this will be considered as a missed visit. The subject may therefore 
still return for subsequent visits and will not be excluded from the investigation.  
8 Study Assessments and Procedures  
Study procedures and their timing are summarized in the schedule of activities (SoA, see 
Section 1.3). Adherence to the study design requirements, including those specified in the 
SoA in Section 1.3, is essential and required for study conduct.  Protocol  waivers or 
exemptions are not allowed.  
All screen ing evaluations must be completed and reviewed to confirm that potential subject s 
meet all eligibility criteria. The investigator will maintain a screening log to record details of 

OXUCT -[ADDRESS_920203] reasons for screening failure, as 
applicable.  
In the event of a significant study -continuity iss ue (e.g., caused by a pandemic), alternate 
strategies for subject  visits, assessments, medication distribution , and monitoring may be 
implemented by [CONTACT_103708], as per local health authority/ethics 
requirements.  
8.1 Evaluations Performed D uring Investigational Visits  
8.1.1 Screening Visit (Visit 1, Days -21 through -2) 
• (Informed ) Consenting  
• Eligibility criteria review  
• Obtaining demographic data and medical history  
• Concomitant medication review  
• AEs and ADEs collection  
• Height, weight, vital signs ( body temperature, blood pressure , and heart rate)  
• Lab assessment  
• Urine pregnancy test for females of childbearing potential  
• Slit-lamp BM (OU)  
• IOP measurement (OU)  
• Best-corrected visual acuity using ETDRS protocol (OU) , duplicate assessments for 
either eye  
• Dilated indirect ophthalmoscopy (OU)  
• Overall assessment of expected procedural complexity (Categories: Low, Medium, 
High)  
• Axial length measurement when available (OU)  
• SD-OCT (OU)  
• OCT -A (OU)  
• Peripheral SS -OCT or UWF SD -OCT when available (OU)  
• Color fundus photographs (OU)  
8.1.2 Baseline visit (Visit 2, Day 0)  
Activities of the baseline visit  can spread over up to  14 days. As facilities with the 
operating/procedure room may not have the full spectru m of ophthalmic assessment or 
imaging devices, the visit schedule varies for an in -clinic  baseline visit  and a baseline visit in 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 56 of 111 an operating/procedure room . If treatment administration in an operating/procedure room is 
intended, some assessments need to b e performed before, as the respective equipment may not 
be present in an operating/procedure room. If the investigator decides for a 2nd treatment 
attempt in an operating/procedure room only a selected number of assessments need to be 
repeated.  
The date fo r calculation of visits following Visit 2, Day 0 will be the date of completion of 
administration of study treatment, i.e., it can be the date of the 2nd attempt for treatment 
administration.  
[IP_ADDRESS]  In-Clinic baseline visit (Visit 2, Day 0)  
Some assessment s only need to be completed after administration of study treatment  (denoted 
as “only post treatment) but not after an unsuccessful treatment attempt as indicated in 
brackets below  (“post attempt”)  
 
Pre-treatment:  
• Eligibility c riteria review, partial: only lab results and updates since screening visit  
• Randomization  
• Concomitant medication review  
• AEs and ADEs collection  
• Urine pregnancy test for females of childbearing age  
• Slit-lamp BM in both eyes (OU)  
• IOP measurement in both eyes (OU)  
• Best-corrected visual acuity using ETDRS protocol (OU)  
• Dilated indirect ophthalmoscopy (OU)  
• SD-OCT (SE)  
Treatment  
• Administration of study medication in study eye (SE)  
Post-treatment:  
• AEs and ADEs collection ( post attempt and post-treatment)  
• IOP measurement in the SE (repeat measurements, at least [ADDRESS_920204]-treatment)  
• Dilated indirect ophthalmoscopy (SE)  (post attempt and post treatment)  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 57 of 111 • SD-OCT (SE)  (post attempt and post treatment)  
• Peripheral SS -OCT o r UWF SD -OCT when available (SE)  (only post treatment)  
• Color fundus photographs (SE)  (post attempt and post treatment)  
• Retinal Physician ’s documentation and assessment of administration procedure  (post 
treatment attempt partially filled in ). 
• Subject ’s experience assessment  (only post treatment ) 
[IP_ADDRESS]  Operating/Procedure Room  baseline visit (Visit 2,  time window for start of V2 
activities  to completion:  14 days ) 
All listed assessments need to be completed.  
This visit variant will be used in case the investigat or: 
• Decides directly to perform the treatment in an operating/procedure room  (“direct to 
OR/PR”)  
• Decides for a 2nd treatment attempt in an operating/procedure room  after a first in -
clinic Visit 2, which did not result in administration of study treatment.  In this case, 
some assessment do not need to be repeated as indicated in brackets below)  
The day of completion of administration of study treatment will be used for calculation of 
further visit dates and windows . 
Pre-treatment:  
• Eligibility criteria review, partial:  (for direct to OR/PR:  only lab results and updates 
since screening visit ), for 2nd  treatment attempt: only updates since first attempt)  
• Randomization  (for direct to OR/PR  mandatory , may be done prior to OR/PR session)  
• Concomitant medication review  (mandatory, may be done prior to OR/PR session)  
• AEs and ADEs collection  (mandatory)  
• Urine pregnancy test for females of childbearing age  (to be performed 1x on the day of 
the treatment attempt)  
• Slit-lamp BM in both eyes (OU , for direct to OR/PR mandatory ; may be done prior to 
OR/PR session ; no rep eat for 2nd treatment attempt ) 
• IOP measurement in both eyes (OU , mandatory ) 
• Best-corrected visual acuity using ETDRS protocol (OU , for direct to OR/PR 
mandatory , may be done prior to OR/PR session ; no repeat for 2nd treatment attempt ) 
• Dilated indirect ophthalmoscopy (OU , mandatory ) 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 58 of 111 • SD-OCT (SE , for direct to OR/PR mandatory , may be done prior to OR/PR session , 
no repeat for 2nd treatment attempt ) 
Treatment  
• Administrati on of study medication in study eye (SE)  
Post-treatment:  
• AEs and ADEs collection  (mandatory)  
• IOP measurement in the SE (repeat measurements, at least [ADDRESS_920205]-treatment , mandatory ) 
• Dilated indirect ophthalmoscopy (SE , mandatory )  
• Retin al Physician’s documentation and assessment of administration procedure  (for 
direct to OR/ PR to be completely filled; completion of previously started version, if 
2nd treatment attempt , mandato ry). 
• Subject’s experience assessment  (post treatment , mandatory ) 
8.1.3 Visits 3 through 9  (Day 1 – Week 20)  
The following visits have evaluation s to be performed as listed below: Visit 3 (Day 1 +1 ), 
Visit  4 (Week 1  ± 3 days), Visit 5 (Week 4  ± 5 days), Visit 6 (Week 8  ± 5 days), Visit 7 
(Week 12  ± 5 days), Visit 8 (Week 16  ± 5 days), and Visit 9 (Week  20 ± 5 days) 
• Concomitant medication review  
• AEs and ADEs collection  
• Urine pregnancy test for females of childbearing age (except for visit 2, Day1 ). 
• Slit-lamp BM (SE), for both eyes (OU) on visit 7 (Week 12  ± 5 days)  
• IOP measurement (SE), for both eyes (OU) on visit 7 (Week 12  ± 5 days)  
• Best-corrected visual acuity using ETDRS protocol (SE) , for both eyes (OU) on visit 7 
(Week 12  ± 5 days)  
• Dilated indirect ophthalmoscopy (SE), for both eyes ( OU) on visit 7 (Week 12  ± 5 
days)  
• SD-OCT (SE), for both eyes (OU) on visit 7 (Week 12  ± 5 days)  
• OCT -A (OU)  on Visit 7 (Week 12 ± 5 days)  
• Peripheral SS -OCT or UWF SD -OCT when available (SE)  
• Color fundus photographs (SE), for both eyes (OU) on visit 7 (Week 12 ± 5 days)  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 59 of 111 • Subject experience assessment  on visits 3 (Day 1 +  1 day), 4 (Week 1  ± 3 days), and 5 
(Week  4 ± 5 days) 
• Follow -on treatment administration if prespecified criteria are met from Visit 5, 
Week  [ADDRESS_920206]  
8.1.4 End of study visit (Visit 10, Week 24± 5  days ) 
• Concomitant medication review  
• AEs and ADEs collection  
• Urine pregnancy test for females of childbearing age.  
• Slit-lamp BM (OU)  
• IOP measurement (OU)  
• Best-corrected visual acuity using ETDRS protocol (OU)  
• Dilated indirect ophthalmoscopy (OU)  
• SD-OCT (OU)  
• OCT -A (OU)  
• Peripheral SS -OCT or UWF SD -OCT using accessory lenses (SE)  
• Color fundus photographs (OU)  
• Follow -on treatment administration if prespecified criteria are met  
8.1.5 Early termination (ET) visit  
Visits in which subjects meet follow -on treat ment criteria as defined in  Section 6.1.8   will be 
considered early termination (ET) visits.  The actual visit schedule will be extended by [CONTACT_680079] (EoS) /Week 24  visit as defined in  Section 8.1.4 . 
8.1.6 Unscheduled visit  
All attempts should be made to keep subjects on the study schedule. However, unscheduled 
visits may be necessary if abnormal findings or AEs occur to evaluate further or repeat testing 
following abnormal findings, or for any other reason, as warranted.  
8.2 Adm inistrative and General/Baseline Procedures  
8.2.[ADDRESS_920207]  (IRB) approval and before any study -related procedure, 
potential subjects will be asked to sign a written informed consent form (ICF)  by [CONTACT_680080] . The subjects will be given sufficient time for the information to 
be read and understood. The subject will be approached and given the chance to ask any 

OXUCT -[ADDRESS_920208]’s demographics, 
medical/surgical history, and factors pertaining to the use of Oxulumis® to administer 
Triesence® to the suprachoroidal space.  
8.2.[ADDRESS_920209] at screening and 
baseline visits is required for eligibility , and then every 4 weeks through  the end of study 
participation (V isit 5-9). 
8.2.4 Concomitant medication review  
Any medication or va ccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the subject receives at the time of enrollment or receives 
during the study shall be recorded at each visit along with:  
• Reason for use  
• Dates of administr ation including start and stop dates  
• Start and stop dates for changes in medications and changes in dose  
• Dosage information including dose and frequency  
The medical monitor should be contact[CONTACT_680081]. 
8.2.[ADDRESS_920210]’s weight, height, and vital signs will be assessed. Vital 
signs include measuring of body temperature, of blood pressure after 5min of sitting in a 
relaxed position, and of heart rate.  If blood pressure values would render subjects not eligible 
per exclusion criterion No. [ADDRESS_920211] 30 minutes prior to blood pressure and pulse measurements.  
8.2.6 Oxulumis® use to administer Triesence® 
Details about the use of Oxulumis® to administer Triesence® are available in the Oxulumis® 
IFU manual.  

OXUCT -[ADDRESS_920212] 's experience during and after the procedure will be collected  in 
interview form (for details see Section 13.1 for the questionnaire  for Visit 2, Day  0, and 
Section 13.2 for Visits 3 through 5 ). 
If the Oxulumis® procedure is repeated after a first  in-clinic attempt with an attempt in an 
operating/procedure room , the subject’ s experience questionnaire will only be completed on 
with completion of administration of the study treatment . 
8.2.8 Retinal physician’s Documentation and Assessment of the 
Administration procedure  
The retinal p hysician will document the procedure details and co mplete the procedure 
assessment questions in the source data  using the questionnaire provided in  Section 13.3. 
If the treatment administration attempts are repeated after  a first unsuccessful in-clinic attempt 
followed by [CONTACT_680082]® procedure in an  operating/procedure room setting, 
only one “ Retinal Physician’s Documentation and Assessment of the Administration 
Procedure ” will be completed with the final procedure reflecting experiences for all 
procedural attempts and treatment.  
8.2.[ADDRESS_920213] Corrected Visual Acuity (BCVA)  
Manifest refraction will be conducted prior to BCVA assessment  at every visit . 
The BCVA assessment will be conducted prior to dilating pupi[INVESTIGATOR_8324], using the standard ETDRS 
protocol at 4 meters with back -illuminated eye charts  and before any other ocular 
proced ures/assessments  requiring contact [CONTACT_680083].  
BCVA in the study eye will be assessed at all visits, as specified in the Schedule of Activities , 
(Section 1.3). All BCVA assessments need to be performed in duplicate. Both measurements 
will be entered in the CRF. For el igibility determination at the screening visit the mean of 
both BCVA assessments will be calculated, if both ETDRS letters scores do not differ by 

[CONTACT_680084] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 62 of 111 more than 5 letters. If the differences are greater  than 5 letters , the better (higher) ETDRS 
letter score wi ll be used. Further details on handling duplicate BCVA assessments will be 
described in the SAP . Refraction only needs to be performed a single time  per visit , if 
duplicate BCVA assessments are performed sequentially , i.e., no other study assessment in 
between the 1st and the 2nd BCVA assessment.  
BCVA assessment will be performed by a certified VA examiner.  
8.3.[ADDRESS_920214] optical biometry 
device ( e.g., partial coherence interferometry (PCI) using the IOL Master (Carl Zeiss Meditec 
AG), LensStar (Haag -Streit, Switzerland), Pentacam AXL (Oculus Optikgeräte GmbH, 
[LOCATION_013]).  Axial length measurement will assess  the axial dimensions of the eye to support 
exploratory i maging of the location of the deployment of study drug in equipped sites only . 
8.3.3 Slit-lamp biomicrosco py 
Subjects’ anterior ocular structure (including the assessment and grading of the lens opacities) 
and ocular adnexa will be examined in the study eye at e ach study visit using a slit lamp, as 
specified in the SoA (Section 1.3).  Slit-lamp biomicroscopy in the fellow eye will be 
performed at screening, baseline, Week  12, and Week 24/ET , as specified in the SoA (Section 
1.3). The exact method for assessing and grading lens opacities/cataracts is described in the 
study procedure manual.  
8.3.4 IOP measurement  
Intraocular pressure (IOP)  of the study eye will be measured at every visit using Goldmann 
applanation tonometry or Tono -pen™, as specified in the SoA (Section 1.3). The same 
method of IOP measurement  as chosen at the screening visit  must be used throughout the 
study for each individual subject  to allow  for comparability of assessments . After the 
treatment intervention on  the baseline visit, IOP  measurement in the study eye must be 
repeated at least twice over a period of 60 minutes after treatment.  
IOP measurement in the fellow eye will be measured at screening, baseline, Week 12, and 
Week 24/ET , as specified in the SoA (Section 1.3). 
8.3.[ADDRESS_920215] ophthalmoscopy  
Subjects’ posterior pole and peripheral retina will be examined by [CONTACT_680085], as specified in  the SoA ( Section 1.3). A 

OXUCT -[ADDRESS_920216] ophthalmoscopy in the fellow eye will be performed  at screening, baseline, 
Week 12, and Week 24/ET , as specified in the SoA (Section 1.3). 
8.3.[ADDRESS_920217] . Key imaging  
parameters are described below but may be adapted  and if necessary extended to fulfill the 
objectives  of this trial. More details w ill be described in more detail in the trial’s  imaging 
manual. All OCT images will be captured and uploaded to a central repository  at a central 
reading center  (CRC)  via an encrypted secure website. All OCTs  images  will be electronically 
archived at the investigational sites as part of the source documentation.  
Acceptable  SD-OCT machines are Spectralis (Heidelberg Engineering GmbH) and Cirrus 
(Carl Zeiss Meditec AG). Other devices would need to be approved by [CONTACT_680086].  In this case, device specific  CST values for eligibility  assessment will be provided as 
for the devices mentioned in inclusion criterion No.4.  The same device should be used for 
screening and the subsequent follow -up assessments for each subject.  
For Spectralis devices the below parameters should be used to acquire two scans:  
• Volume Scan (cent ered on the fovea): 20° x 20°, 97 Section with ART set to 16 and 
High -Resolution  mode (HR)  
•  Volume Scan (centered on the fovea): 30° x 5°, 7 Section with ART set to 25 and HR) 
For Cirrus devices the below parameters should be used to acquire two scans:  
• 512x128 Macular Cube  
• HD [ADDRESS_920218] (will be assessed in sites with available capabilities using appropriate 
imaging parameters ). 
OCT imaging, i.e., SD-OCT and, when available  peripheral  OCT, will  be performed at each 
visit for the study eye.  Exception s are: 
• If the Oxulumis® procedure is not completed, only a post treatment attempt SD -OCT 
is required. The optional peripheral OCT is not assessed, as its main purpose is to 
visualize  the suprachoroid al drug bleb post study treatment.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 64 of 111 • If the Oxulumis® procedure is completed in an operating/procedure room with neither 
access to an SD -OCT  nor Peripheral OCT  in this facility on Day 0, Visit 2, these are 
not required to be performed post treatment. Assessm ents on Day [ADDRESS_920219] -Angiography  
The anatomical state of the retinal vasculature will be evaluated by [CONTACT_680087] (OCT -A). Key imaging parameters are described  below but may be 
adapted and if necessary extended to fulfill the objectives  of this trial. More details will be 
described in more detail in the trial’s imaging manual. OCT -A images will be captured and 
uploaded to a central repository at a CRC via an encrypted secure website . All OCT -As will be 
electronically archived at the investigational sites as part of the source documentation.  
The preferred OCT -A machine for retinal vasc ular diseases is the ZEISS PlexElite.  The 
Optovue can also be used but may have fewer wide -angle choices. The same device should be 
used for screening and the subsequent follow -up assessments for each patient. The preferred 
scan acquisition protocols for retinal vasculopathies are 3x3 and 9x9 scans.  
OCT -A imaging, will be performed at screening , Week 12,  and Week 24/EOS visits, as 
specified in the SoA  (Section 1.3). 
8.3.8 Color fundus photography  
Retinal anatomy will be evaluated by [CONTACT_680088] (CFP).  In case of non -
completion of the procedure in the clinic, a CFP is required to be acquired in the study eye . 
Key imaging parameters are described below but may be adapted and if necessary extended to 
fulfill the objectives  of this trial. More details will be described in more detail in the trial’s 
imaging manual . Fundus photography will be captured and uploaded to a central repository at 
a CRC  via an encrypted secure website.  All CFPs will be archived at the site as part of the 
source documentation.  
CFP in the study eye will be captured at all visits, as specified in the SoA (Section 1.3). If the 
Oxulumis® procedure is completed in an operating/procedure room with no access to a CFP i n 
this facility on Day 0, Visit 2, it is sufficient to perform the CFP foreseen for Day 1, Visit 3.  
CFP in the fellow eye will be captured at screening, Week 12, and Week 24/ET , as specified 
in the SoA (Section 1.3). 

OXUCT -[ADDRESS_920220] has met follow -on treatment criteria in the study eye 
and before follow -on treatment is given.  
CFP will be capture d using either 4WF or UWF imaging  methods  (see Table 4). Additional 
images to document the site of drug deployment using infra -red imaging  will be taken.  
4 Wide Field imaging  (4WF) :  Take one FR (Fundus Reflex) and stereo pairs of F1W and 
F2W, and single images F4W and F5W o f each eye for a minimum of 7 images per eye, 14 
total images OU. In addition, infra -red images of the site of deployment  will be taken.  
Ultrawide Field (U WF) imaging:  Perform 2 Central Wide Field single images. In addition, 
infra -red images of the site of  deployment  will be taken.  
Table 4  Overview of Imaging Systems and Required Field of View for Wide -Field 
Color Funds Photographs  
Imaging System  Required Image Field of View (FOV)  
Clarus  Take all images at 133 -degree capture mode  
Optos  Take all images at 200 -degree capture mode  
Spectralis  Take all images using a 102 -degree lens using ART 15  
8.4 Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoAs in Section 1.3. 
The f ollowing assessments will also provide safety -relevant information but are discussed in 
other sections: IOP assessment (Section 8.3.4 ), slit -lamp biomicroscopy ( Section 8.3.3 ), 
dilated indirect ophthalmoscopy ( Section 8.3.5 ), SD -OCT ( Section 8.3.6 ). and pregnancy test 
(Section 8.2.3 ). 
8.4.[ADDRESS_920221] collection  
At every visit, the investigator (or designee) will assess for and record all adverse events 
(AEs) and adverse device effects ( ADEs ) that occur from the time the informed consent is 
signed until the end of the study.  
8.4.2 Safety laboratory tests  
Blood samples for routine clinical laboratory tests will be collected at the screening visit 
(Visit 1, D -21 to -2). Screening laboratory tests will be performed in local CLIA certified 
laboratories . Tests may be repeated once at the discretion of the investigator. The minimum 
tests to be performed include the following:  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 66 of 111 • Non-fasting chemistry (blood): sodium, potassium, chloride, bicarbonate, albumi n, 
alkaline phosphatase, aspartate amino transferase, alanine amino transferase, bilirubin 
direct, bilirubin indirect, total bilirubin, creatinine, blood urea nitrogen, total protein, 
calcium, phosphorus, and hemoglobin A1c  
• Hematology (complete blood count  with differential): white blood cell count, red 
blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean 
corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red cell 
distribution width, platelet count, and mean platelet volum e 
• Thyroid: thyroid -stimulating hormone  
The investigator shall review the laboratory report, document the review, and record any 
clinically significantly abnormal findings . Clinically significant abnormal findings from the 
screening laboratory testing that are explained by [CONTACT_680089] (CRF). If the screening laboratory assessments detect new, clinically significant 
abnormal findings, t hat are not explained by [CONTACT_680090], such findings 
should be recorded as non -treatment -emergent AE. The laboratory reports shall be filed with 
the source documents.   
If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in subject management or are considered 
clinically significant by [CONTACT_093], then the results shall be recorded in the CRF.  
8.4.[ADDRESS_920222] 30 minutes 
prior to blood pressure and pulse measurements. Height and Weig ht will be used calculate the 
BMI (kg/m ²). 
8.5 Safety Reporting , Adverse Events (AEs) , and Serious Adverse Events (SAEs)  
All subjects enrolled to the study treatment will be assessed for safety.  
Investigators are responsible for monitoring the safety of subjec ts who have entered this study 
and for alerting the Sponsor regarding any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the subject. The Investigator is responsible for 
appropriate medical care of subjects durin g the study.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 67 of 111 The definitions of adverse events (AEs) and serious adverse events (SAEs)  considering the 
definitions also of 21 CFR 3 12.31(a)  can be found in  Section 11. 
The definitions of device -related safety events  including  adverse device effects (ADEs), 
device deficiencies, and serious adverse device effects (SADEs) can be found in  Section  11.3, 
Section 11.4, and Section  11.6. 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up all AEs  OR AEs that are seri ous, considered related to the study intervention or 
study procedures, or that caused the subject  to discontinue the study (see Section 7). This 
includes events reported by [CONTACT_423]  (or, when appropriate, by a caregiver, surrogate, or the 
subject ’s legally authorized representative).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in  Section  11.7. 
8.5.1 Time Period and Frequency for Collecting AE and SAE Information  
All AEs/ SAEs will be collected from the signing the ICF  until EoS/ET visit (Week 24) at the 
timepoints specified in the SoA ( see Section 1.3). 
A preexisting medical condition is  one that had been already present at the start of the study 
(at the time of the signature [CONTACT_48028]). Such conditions should be recorded on the Medical 
and Surgical History eCRF .  The AEs and SAEs that begin between  obtaining the signed ICF 
and the start of study intervention  will be categorized  as non-treatment emergent AEs/SAEs.  
This also includes  AEs/SAEs, which continue after the start of study intervention  but do not 
worsen in severity.  
The AEs and SAEs that begin after start of the study inter vention , and those  existing pre -dose 
that worsened in severity post -dose will be considered treatment -emergent AEs and SAEs.  
A pre -existing medical condition should be recorded as an AE or SAE only if the frequency, 
severity, or character of  the condition worsens during the study. When recording such events 
on an AE eCRF and SAE form (if applicable), it is important to convey the concept that the 
preexisting condition has changed by [CONTACT_9672] ( e.g., “more frequent 
headaches”).  
All SAE s will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed [ADDRESS_920223] promptly notify the sponsor . 
8.5.2 Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading  verbal questioning of the subject  is the preferred method to inquire about AE 
occurrences.  To limit bias  in safety reporti ng, subjects are masked to their dose level. The 
study team must not disclose the dose level received until after the end of the study  except for 
emergency situations.  
8.5.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject  
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the 
event is otherwise explained, or the subject  is lost to follow -up (as defined in Section 7.4). 
Further information on follow -up procedures is provided in Section 11.7.4 . 
8.5.4 Disease -related events and/or Disease -related outcomes not qualifying 
as AEs or SAEs  
No specific disease -related events not qualifying as AEs or SAEs are defined for thi s clinical 
trial. Significant and unexpected loss in VA or parameters indicating an increase of macular 
edema may be reported as AE if the extent is significant or unexpected in the opi[INVESTIGATOR_5521]. Non -improvement or worsening of di sease leading to need for follow -
on treatment (as defined in  Section 6.1.8 ) would only qualify as an AE, if significant or 
unexpected in the opi[INVESTIGATOR_871].  
8.5.5 Regulatory Reporting Requirements for Serious Safety Events  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
sponsor will comply with country -specific regulatory requireme nts relating to safety reporting 
to the regulatory authority, IRBs/IECs, and investigators.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 69 of 111 Safety reporting to the regulatory authorities will be performed according to the following 
regulations applicable to the US : 
• IND safety reporting Guidance for Indu stry and Investigators - Safety Reporting 
Requirements for INDs and BA/BE Studies (US FDA , 2012 ) 
• Guidance Sponsor Responsibilities - Safety Reporting Requirements and Safety 
Assessment for IND and Bioavailability/Bioequivalence Studies for Investigators (US 
FDA, 2021a ) and Sponsors (US FDA 2021b ) 
The detailed information on safety reporting timelines and processes according to the above 
regulations will be outlined in the Safety  Monit oring Plan . 
8.5.[ADDRESS_920224] (AESIs) are defined and monitored following 
the same expedited reporting as used for SAEs (see  Section  8.5.1 ). AESIs comprise the 
following prespecified terms based on general considerations on potential safety risks with 
suprachoroidal device deployment and treatment.  
• Suprachoroidal hemorrhage  
• Sterile intraocular inflammation  
• Endophthalmitis  
• Choroidal bacterial infection  
• Retinal detachment  
• Retinal perforation  
• Rise of intraocular pressure above 30 mmHg  
• Rise of at least 10 m mHg from baseline IOP  
• Severe pain or discomfort after administration of IP  
To consider an acute IOP rise after the treatment administration procedure as an AESI, the 
rise must continue beyond the 60min observation period on Day 0, Visit 2, or require medic al 
intervention, e.g., a paracentesis to lower IOP.  For a persistent rise of the IOP detected upon 
the follow -up visits, to consider it as meeting AESI criteria, the rise must be maintained over 
2 successive visits.  
8.5.7 Device Deficiencies  
Oxulumis® devices a re being provided for use in this study to administer Triesence® as part of 
the study intervention. To fulfill regulatory reporting obligations worldwide, the investigator 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 70 of 111 is responsible for the detection and documentation of events meeting the definitions  of device 
deficiency that occur during the study with such devices.  
The definition of a medical device deficiency as well as processes and time periods for 
detection, notification, reporting, and follow -up of the medical device deficiencies can be 
found in Section 11.4. 
NOTE: Deficiencies fulfilling the definition of an AE/SAE will follow the processes outlined 
in Sections  8.5 of this protocol.  
8.5.8 Contraception Guidance  
According to the USPI [INVESTIGATOR_680050]®, (Alcon Laboratories Inc. , 2007 ), administration in 
pregnancy can cause f etal harm with first trimester use. Multiple cohort s and case -control 
studies in humans suggest that maternal corticosteroid use during the first trimester increases 
the rate of cleft lip with or without cleft palate from about 1/1000 infants to 3 - 5/[ADDRESS_920225] an increased risk for 
intrauterine growth restriction and decreased birth weight. An inde pend ent overview and 
discussion of th ese effects w ere recently compi[INVESTIGATOR_680051]. (Bandoli et al. , 
2017 ). 
Accordingly, and following the g uidance on contraception of the Clinical Trial Facilitation 
Group  (Clinical Trials Facilitation and Coordination Group , 2020 ), the following 
contraception  guidance needs to be implemented in this study and is also mentioned in the 
inclusion criteria in  Section 5.1. 
The following methods are considered highly effective as they can achieve a failure rate of 
less than 1% per year when used consistently  and correctly .  
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation  
o oral 
o intravaginal  
o transdermal  
• progestogen -only hormonal contraception associated with inhibition of ovulation  
o oral 
o injectable  
• implantable  
• intrauterine device  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 71 of 111 • intrauterine hormone -releasing system  
• bilateral tubal occlusion  
• vasectomised partner  
• sexual abstinence  
Alternatively, two methods ( e.g., two barrier methods such as a condom and a cervical cap) 
may be combined to achieve a failure rate of less than 1% per year;  barrier methods must 
always be supplemente d with the use of a spermicide.  
Women who are not postmenopausal , i.e., at least  12 months of non -therapy -induced 
amenorrhea or surgically sterile (absence of ovaries and/or uterus) , must agree to remain 
abstinent or use combined contraceptive methods that  result in a failure rate of less than 1% 
per year from the treatment visit (Day  0) until the end of trial participation , or for at least  12 
weeks from the treatment visit (Day 0), if study participation ends before visit 7, Week 12.  
Some forms of contraception , e.g., hormonal contraception , need to be started befo re the 
treatment visit (Day 0) to have full effect from the time of exposure on.  
Male  participants  must agree to use a barrier method of contraception from the treatment visit 
(Day  0) unti l the end of trial participation , or for at least  [ADDRESS_920226] (after obtaining the 
necessary signed ICF from the female partner . 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication o r 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs and will be reported as such. Any post  
study pregnancy -related SAE considered reasonably related to the study intervention by [CONTACT_99480]  8.[ADDRESS_920227]/pregnant female partner will be followed to determine the outcome of the 
pregnancy. The investigator will collect follow -up information on the subject/pregnant female 

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 72 of 111 partner and the neonate (after obtaining a signa ture of pregnancy follow -up specific ICF) and 
the information will be forwarded to the sponsor.  
Any female subject who becomes pregnant while participating in the study will not be treated 
with the study intervention when the pregnancy becomes apparent bef ore treatment 
administration at V isit 2. If the pregnancy is detected after administration of study treatment, 
the patient will be offered to attend study visits for a safety follow -up with non -invasive 
assessments only (as standard at the relevant site for the assessment of pregnant patients).  
9 Statistical Considerations  
This is  a 24-week, randomized, two -arm, parallel -group, single -masked, clinical trial  to 
evaluate safety and tolerability of two dose levels of suprachoroidal triamcinolone Acetonide  
Administered with the Oxulumis® ophthalmic administration in subjects with Diabetic 
Macular Edema . 
9.1 Statistical Hypothesis  
The present clinical trial is a single -masked , two-arm study to evaluate safety and tolerability  
of two dose levels , therefore  no formal statistical hypothesis was developed.  
9.2 Sample Size Determination  
A total of approximately 20 subjects will receive a single treatment with Triesence® 
administered with the Oxulumis® to one eye, the study eye.  Subject s in whom study treatment 
cannot be administered  will be replaced.  
The sample size is not based on power calculations. It is chosen based on clinical experience 
and considered to be adequate to fulfi ll the objectives of the clinical trial . A sample size of  [ADDRESS_920228] common and very common adverse events, which is key to 
inform further trials in the Oxulumis® development  program in respect to safety 
considerations . 
9.3 Analysis Sets  
In this clinical trial , the following definitions for a nalysis sets will apply.  
9.3.1 Safety Popula tion 
The safety population (SAF) will include all subjects in whom the administration of study 
treatment was started.  
OXUCT -[ADDRESS_920229] baseline efficacy observation or measurement  in the study eye ( i.e., 
either BCVA or CST) . 
9.3.3 Per Protocol Efficacy Population  
The per protocol efficacy population (PP) consists of the Efficacy Evaluable Population with 
the exception  of subjects with important protocol violations.  
9.4 Statistical Analyses  
9.4.1 General  Considerations  
All statistical analyses will be outlined in detail in a Statistical Analysis Plan (SAP) which 
will be prepared and signed prior to databa se lock or any study -specific analyses. Summary 
statistics from investigator findings will be tabulated and summarized descriptively.  Where 
applicable, treatment arms of 2.4mg and 4.0mg will be compared with descriptive statistics.  
All continuous measures will be summarized  descriptively, including the number of available 
values, minimum, 1st quartile, median, mean, standard deviation, 3rd quartile, maximum, and 
95% confidence interval for the mean, if appropriate. Categorical data will be presented by 
[CONTACT_7237]. Ordinal ratings may be handled as continuous data if appropriate or  
presented as categorical if the number of categories is small.  
9.4.2 Safety Analyses  
All safety analyses will be performed on the SAF population.  
The treatment -emergent AE s/ADEs (defined as any AE occurring or worsening with the same 
date or later than that of the first application of study treatment) will be encoded using the 
MedDRA version 24.1. This version will be used throughout the entire study. If available, 
updates of the MedDRA dictionary will not be applied afterwards.  
The treatment -emergent AEs or ADEs will use the system organ class (SOC) and preferred 
term (PT) codes.   
TEAEs, study drug -related AEs, AEs of Special Interest (AESIS), AEs leading to withdrawal 
from  the study and SAEs will be summarized  in a similar manner.  AEs will be presented 
categorized as ocular and non -ocular AEs.  Ocular AEs will be presented separately for the 
study  eye and the non-study  eye. 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 74 of 111 9.4.3 Exploratory Efficacy and Safety Endpoint Analysis  
The following main exploratory endpoint s will be described on efficacy evaluable population 
and per protocol efficacy population (if different):  
1. Mean Change in BCVA (ETDRS) at all study visits through Week [ADDRESS_920230] 15 letters at all study visits through Week 24 compared to baseline  
3. Time to subjects requiring follow -on treatment  
4. Mean Change in Central subfield thickness (CST) at all study visits through Week [ADDRESS_920231] quartile, maximum, and 
95% confidence interval for the mean, if appropriate. Categorica l data will be presented by 
[CONTACT_7237]. Ordinal ratings may be handled as continuous data if appropriate or  
presented as categorical if the number of categories is small.  
9.4.[ADDRESS_920232] on the perceived efficacy and/or safety of study treatments.  
As important protocol violations are considered:  
• Not meeting t he inclusion criteria or meeting the exclusion criteria, respectively  
• Missing study visits or out of window study visits  (depending on type of visit and on 
the time interval).  
• Intake of non -authorized concomitant treatment  
• Missing important safety data points (IOP measurements, dilated fundus examinations, 
BCVA measurement, SD -OCT measurement, etc.)  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 75 of 111 9.4.5 Other Analyses  
[IP_ADDRESS]  Subject Disposition and Baseline Characteristics  
Subject disposition will include the number of subjects who enroll  in the study and the 
numbe r and percentage of subjects included in each analysis population. The frequency and 
percentage of subjects who discontinue from the study, along with the reason for 
discontinuation, will be summarized. Demographics and baseline characteristics, including 
age, gender, and race will be summarized using descriptive statistics for the SAF population.  
[IP_ADDRESS]  Concomitant Medications  
For previous and concomitant medications,  the original terms will be recorded on the Study 
Subjects’ eCRF by [CONTACT_093]. Previous and concomitant medications will not be coded, 
and verbatim original terms recorded on the eCRF will be presented as data listings.  
[IP_ADDRESS]  Physician Procedure Assessmen t 
Physician procedure assessment will be described on the Safety Population (SAF).  
[IP_ADDRESS]  Patient Experience Assessment  
Patient experience assessment will be described on the Safety Population (SAF) at study 
visits.  
9.4.6 Missing Data and Imputation Methods  
No imputati on of missing data will be performed.  
In case the start date for an AE/ADE is missing or incomplete, so that it is not possible to 
evaluate if it has occurred pre - or post -treatment, this AE/ADE will be classified 
conservatively as treatment -emergent.  
9.[ADDRESS_920233] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 76 of 111 Observable and data -driven protocol deviations will be recorded and categorized in a central 
protocol deviation log.  
Relevant information for each protocol deviation will be documented on a deviation form.  
Protocol  deviations shall be reported to regulatory authorities in specified timelines as 
appropriate.  
9.6 Interim Analysis  
To compi[INVESTIGATOR_680052]® device , Oxular Ltd. intends to perfo rm an 
analysis on clinical data up to Week [ADDRESS_920234] their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP and applicable regulatory 
requirements. The sponsor or the sponsor’s representatives will obtain regulat ory approval 
from the competent authority prior to the clinical trial  start.  The sponsor will provide all 
necessary documents to obtain such approval.  
If any of the documents relevant to obtain ing approval are amended, the sponsor or the 
sponsor’s represen tatives will submit these documents for review and subsequent approval to 
the competent authority.  
An annual safety /progress report will be provided by [CONTACT_352442]’s 
representatives to the competent regulatory authority  as required by [CONTACT_680091] . 
The sponsor or the sponsor’s representatives will obtain ethical approval from the Institutional 
Review Board (IRB) prior to the clinical trial  start. The sponsor will provide all necessary 
documents to obtain such approval.  
If any of the  documents relevant to obtain ing approval are amended, the sponsor or the 
sponsor’s representatives will submit these documents for review and subsequent approval to 
the IRB.  
The investigator is responsible for accuracy and completeness of all data recorded  in patient 
medical charts and CRFs.  All data recorded in the CRF are derived from source data unless 
specifically exempted. Source data will be defined prior to the start of the clinical trial but  
consists in general of the information documented in the patient medical chart.  Corrections to 
data should be made in a way so that the originally recorded data is still legible and traceable. 
Any changes should be initialed and dated by [CONTACT_36324]. The 
investigator will maintain a file of  essential documents of the trial as defined by [CONTACT_145029], ICH, and the sponsor.  
10.2 Financial Disclosure  
Financial compensation of the investigator and/or his/her institution will be regulated in a 
financial agreement established between the  sponsor or the sponsor’s representative and the 
investigator and/or his/her institution.  
OXUCT -[ADDRESS_920235] arisen after reading the ICF.  
The sponsor’s sample ICF will be provided to each site. If applica ble, it will be provided in a 
certified translation of the local language. The sponsor or its designee must review and 
approve any proposed deviations from the sponsor's sample ICFs before IRB submission. The 
final IRB approved Consent Forms must be provid ed to the sponsor for health authority 
submission purposes according to local requirements.  
The Consent Forms must be signed and dated by [CONTACT_680092]. The case history or clinical records for each patient shall document the ICF process 
and that written ICF was obtained prior to participation in the study.  
Patients unable to give consent personally will only be consented in those countries where 
national law/regulations permit.  
The Consent Forms should be revised whenever there are changes to study procedures or 
when new information becomes available that may affect the willingness of the patient to 
participate. The final revised IRB -approved Consent Forms must be provided to the sponsor 
for health authority submis sion purposes.  
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and IRB 
policy) during their participation in the study. For any updated  or revised Consent Forms, the 
case history or clinical records for each patient shall document the ICF process and that 
written ICF was obtained using the updated/revised Consent Forms for continued 
participation in the study.  
A copy of each signed Consen t Form must be provided to the patient. All signed and dated 
Consent Forms must remain in each patient’s study file or in the site file and must be 
available for verification by [CONTACT_9534].  
10.[ADDRESS_920236] parties as permitted by [CONTACT_9535] (or separate authorization for use and disclosure of 
personal heal th information) signed by [CONTACT_680093]. 
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare  for treatment purposes.  
Data generat ed by [CONTACT_680094], sponsor monitors, representatives, and 
collaborators, and the IRB for each study site, as appropriate.  
All reasonable precautions within the constraints of the applicable regulatory requirement(s) 
will be taken to maintain the confidentiality of subjects' identities and sponsor’s proprietary 
information by [CONTACT_680095] ( e.g., domestic and foreign regulatory author ities, sponsor's 
monitors, and auditors) with direct access to patient medical information.  
The data protection officer of the clinical study site and the sponsor must be informed about 
the project before the start of a clinical study. The data protection officer is obligated to 
monitor compliance with the requirements of all data protection regulations. The data 
protection officer must, therefore, not only be informed but all necessary information must be 
provided so that the data protection officer can fu lfill his or her inspection obligations.  
In case of a data security breach, the data protection officer needs to be informed. The data 
protection officer is required to report the breach immediately (within 72h) to the responsible 
data protection supervis ory authority. Subjects who are personally concerned and potentially 
endangered by a data protection breach will be informed immediately. Any possible measure 
to remedy the data protection breach will be arranged. Appropriate technical and 
organizational  measures are implemented to protect information and personal data processed 
against unauthorized  or unlawful access, disclosure, dissemination, alteration, destruction , or 
accidental loss, in particular where the processing involves the transmission.  
OXUCT -[ADDRESS_920237] records or datasets 
that are transferred to the sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred . 
The subject must be informed that their personal study -related data will be used by [CONTACT_20004]. The level of disclosure must also be 
explained to the subject who will be required to give consent for their dat a to be used as 
described in the informed consent.   
The subject must be informed that their medical records may be examined by [CONTACT_384303], by [CONTACT_99473]/IEC members,  and by  [CONTACT_6668].  
10.5.1  Committee Structure  
[IP_ADDRESS]  Safety Committee  
Periodically, the coordinating investigator [INVESTIGATOR_680044], continue with changes , or be terminated.  
[IP_ADDRESS]  Study Steering Committee  
The study will use the services of a study steering committee (SSC). The composition, roles, 
responsibilities,  and rules governing the SSC are available i n the SSC Charter.  
10.5.[ADDRESS_920238] a need to know, the 
protocol, the  data arising out of the study, and any other information related to the study or to 
Sponsor’s products or research programs that is provided to the Investigator. All such persons 
must be instructed not to further disseminate this information to others. In vestigators shall not 
use the confidential information for any purpose other than the study. The foregoing 
obligations of confidence and non -use assumed by [CONTACT_680096]:  
a. information which at the time of disclosure is in the public domain;  
b. information which thereafter lawfully becomes part of the public domain other than 
disclosure by [CONTACT_680097];  
c. information which, as evidenced by [CONTACT_737]’s written records, was known 
by [CONTACT_680098]’s disclosure;  
OXUCT -[ADDRESS_920239] party not under 
any obligation of confidence to Oxular Limited; or  
e. information which is required to be disclosed by [CONTACT_7720] a government  regulatory 
agency, provid ed reasonable advance notice of such disclosure is given to Oxular 
Limited.  
All data and discoveries arising out of the study, patentable or non -patentable, shall be the 
sole property of Oxular Limited. Oxular Limited reserves the right to prior review of any 
publication or presentation of information related to the study. Oxular Limited reserves the 
right to prior review of any publication or presentation of information related to this study. 
Oxular Limited may use these data now or in the future for prese ntation or publication at 
Oxular Limited’s discretion or for submission to Regulatory Authorities.  
10.5.[ADDRESS_920240] by [CONTACT_18027].  
The sponsor is responsible for the data management compliance of this study, including 
quality checking of the data, and assumes accountability for actions delegated to other 
individuals. Authorized representatives of the sponsor may perform audits or inspections, 
including source data verification. The purpose of an audit or inspection is to systematically 
and independently examine all study -related activities and documents to determine whether 
these activities were conducted, and data were recorded, analyzed, and accurately reported 
according to the protocol, GCP guidelines of the ICH, and any applicable local regulatory 
requirements. The Investigator agrees to accommodate and participate in audits conducted at a 
reasonable time and in a reasonable manner. The Sponsor’s clinical quality assurance group 
may request access to all source documents, eCRFs, and other study documentation for on -
site audit or inspection.  
Direct access  to these documents must be guaranteed by [CONTACT_737], who must provide 
support at all times for these activities. Additionally, the investigational site shall provide 
direct access to all trial -related sites, source data/documents, and reports for th e purpose of 
inspection by [CONTACT_3482]. In the event of this latter, the Investigator shall 
contact [CONTACT_167449] a regulatory agency about an inspection.  
QC procedures shall be implemented beginning with the data entry system, and data QC 
checks that will be run on the database shall be generated. Any missing data or data anomalies 
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 82 of 111 shall be communicated to the site(s) for clarification/resolution. Following written SOPs, the 
monitors will verify that the clini cal trial is conducted, and data are generated, documented 
(recorded), and reported in compliance with the protocol, GCP and applicable regulatory 
requirements.  
Clinical study records shall be retained according to the following requirements, unless local 
regulations or institutional policies require a longer retention period than summarized:  
• US regulations (21 CFR Part 312.62) require that records and documents pertaining to 
the conduct of this study and the distribution of investigational products (including 
medical records, eCRFs, ICFs, test results, and investigational product records) be 
kept on file by [CONTACT_13177] [ADDRESS_920241] be kept for 2 years after the 
investigation has been discontinued and the FDA has been notified.  
• ICH-GCP requires that documents should be retained until at least [ADDRESS_920242] medical records with dates and details of the trial procedures 
(screening, laboratory and other test results, study treatments, AEs, and subject status, etc.). 
The source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. These source documents shall be filed at the investigator’s site.  
The sponsor will provide the study sites with eCRFs that will be completed for each study 
subject based on  the source documentation. It is the Investigator’s responsibility to ensure the 
accuracy, completeness, legibility, and timeliness of the data reported in the subject’s eCRF.  
Data reported on the CRF or entered in the eCRF that are transcribed from sourc e documents 
OXUCT -[ADDRESS_920243] 
completes the clinical trial. An explanation shall be provided for all missing data.  
The sponsor’s representative will perform monitoring to confirm that data entered into the 
CRF by [CONTACT_1191], complete, and v erifiable from source 
documents , that the safety and rights of subjects are being protected , and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory req uirements.  
10.[ADDRESS_920244] site open and  will be the study start date.   
10.7.2  Study/Site Termination  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been co llected and a study -site closure visit has been performed.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 84 of 111 Further to regulations  outlined in  Section 7, reasons for the early closure of a study site by [CONTACT_581920]:  
For study termination:  
• Discontinuation of further study intervention development  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB or 
local health authorities, the sponsor’s procedures, or GCP guidelines  
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of subject s 
by [CONTACT_093]  
• Total number of subject s included earlier than expected  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the subject  and sh all assure 
appropriate subject  therapy and/or follow -up. 
11 Safety : Events , Definit ions and Procedures  
11.1 Emergency Contacts for Investigator Reporting of Safety Events  
The primary mechanism for reporting an SAE/SADE/AESI to Sponsor will be the electronic 
data capture system (EDC) . The site will enter the SAE/SADE/AESI data into the electro nic 
system as soon as it become s available . If the EDC system is unavailable for a period of time 
which  will not allow reporting within 24 hours, the (paper) SAE/SADE/AESI  forms will be 
sent by [CONTACT_680099] 24 hours . Contacts for SAE reporting can be found in 
the Investigator Site File . 
11.2 Adverse Event (AE)  
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug -related.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study intervention and does not imply any judgment of causality.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 85 of 111 11.3 Device Adverse Event (A E) and A dverse Device Effect (ADE)  
The AE definition provided in  Section 11.[ADDRESS_920245] s (ADE) , which  is defined as an AE 
related to the us e of an investigational medical device . This definition includes any AE 
resulting from insufficient or inadequate instructions for use, deployment, implantation, 
installation, or operation, or any malfunction of the investigational medical device as well a s 
any event resulting from use error or from intentional misuse of the investigational medical 
device.  
11.4 Device Deficiency  
Device deficiency  is defined in ISO [ZIP_CODE]:[ADDRESS_920246] has 
received drug administration with the device or has been discharged from the study, and such 
a deficiency is considered reasonably related to a medical device provided for t he study, the 
investigator will promptly notify the sponsor.  
11.4.2  Follow -up of Device Deficiencies  
The following principles for follow -up will be applied for device deficiencies:  
• Follow -up applies to all subjects, including those who discontinue study intervention.  
• The investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the deficiency.  
• New or updated information will be recorded on the originally comple ted form with 
all changes signed and dated by [CONTACT_093].  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 86 of 111 11.4.3  Regulatory Reporting Requirements of for Device Deficiencies  
The sponsor will report:  
1. Device deficiency -related SAEs and SADEs , observed either during the drug 
administration procedure or subsequently reported by [CONTACT_431] (see below) as 
expedited safety reports following the guidelines in Section  8.5.5 . 
2. Non-serious AEs due to device deficien cies (including but not limited to “failure to 
treat”  with the device) will be reported in the  annual DSUR as part of the IND annual 
reporting requirement s of 21 CFR 312.33.  
The following regulations apply for reporting of Device Deficiencies to the Sponsor : 
1. Any device deficiencies will be reported to the sponsor within [ADDRESS_920247]-treatment ,  with any medical device provided for use in the study for 
the sponsor to fulfill the legal responsibility to notify appropriate regulatory authorities and 
other entities about certain safety information relating to medical devices being used in 
clinical studies.  
The investigator, or responsible person according to local requirements, will comply with the 
applicable local regulatory requirements relating to the  reporting of SAEs or SADEs 
determined to be device deficienc y-related  to the IRB/IEC.  
11.5 Serious Adverse Event (SAE)  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more 
of the criteria listed (for the US CFR 312.32(a) applies):  
a. Results in death  
b. Is life -threatening  

OXUCT -[ADDRESS_920248] 
was at (immediate) risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_680053], hospi[INVESTIGATOR_512192] (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment 
that would not have been appropriate in the ph ysician’s office or outpatient setting. 
Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs 
hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to 
whether hospi[INVESTIGATOR_178421] o r was necessary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
The term disabili ty means a substantial disruption of a person’s ability to conduct normal life 
functions.  
This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,  and accidental trauma 
(e.g., sprained ankle) that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other important medical events:  
Medical or scientific judgment sho uld be exercised by [CONTACT_680100] -threatening or result in death or hospi[INVESTIGATOR_233051] t or may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition. These events should usually be considered 
serious.  
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not 
resulting in hospi[INVESTIGATOR_059], or development of intervention dependency or intervention abuse.  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 88 of 111 According to the US FDA guidance, the determination of the categorizati on of an event, e.g., 
as serious or life -threatening, can be based on the opi[INVESTIGATOR_109873] 
(US FDA , 2012 ). 
11.[ADDRESS_920249] will be performed (European Parliament/Council (EC) 2017 ). The seriousness criteria 
here are slightly different from the SAE criteria outlined in  Section 11.5. 
A Medical Device SAE  is any serious adverse event that led to  
a. death  
b. serious deterioration in the health of the subject, that either resulted in:  
• A life -threatening illness or injury.  
• A permanent impairmen t of a body structure or a body function.  
• Hospi[INVESTIGATOR_13266]. Planned hospi[INVESTIGATOR_272] a pre -existing 
condition, or a procedure required by [CONTACT_760], without serious deterioration in 
health, is not considered an SAE.  
• Medica l or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.  
• Chronic disease (European Parliament/Council (EC) 2017 ). 
c. Led to fetal distress, fetal death, or a congenital abnormality or birth defect  
A serious adverse device effect (SADE)  is defined as an adverse device effect that has 
resulted in any of t he consequences characteristic of an SAE.  
Any device deficiency that might have led to an SAE if appropriate action had not been taken, 
the intervention had not occurred, or circumstances had been less fortunate.  
An unexpected serious adverse device effect  [LOCATION_003]DE  (also identified as UADE in US 
Regulations 21 CFR 813.3), is defined as a serious adverse device effect that by [CONTACT_5942], 
incidence, severity, or outcome has not been identified in the current version of the risk 
analysis report for the device.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 89 of 111 11.7  AE and SAE Recording  
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event. The investigator will then record all rel evant AE/SAE information.  
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_014]/digital copi[INVESTIGATOR_9238]’s 
medical records to Oxular Ltd. or its delegates in lieu of completion of the SAE report form.  
There may be instances when copi[INVESTIGATOR_680054]. In this case, all subject identifiers, except for the subject number, 
must be redacted on the copi[INVESTIGATOR_680055]. or its 
delegates.  
The in vestigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Investigators should use corre ct medical terminology/concepts when recording AEs or SAEs 
on the eCRF and/or SAE form. Colloquialisms and abbreviations should be avoided. Serious 
AEs must also be recorded on the AE eCRF. Only 1  medical concept should be recorded in 
the event field on th e AE eCRF and SAE form (if applicable).  
Adverse Events Occurring Secondary to Other Events  
In general, AEs occurring secondary to other events ( e.g., cascade events or clinical sequelae) 
should also be entered as separate AEs. For example, if severe diarrh ea is known to have 
resulted in dehydration, both diarrhea and dehydration should be entered as AEs on the eCRF, 
and if also serious, on the SAE form.  
Persistent or Recurrent Adverse Events  
A persistent AE extends continuously, without resolution between subject evaluation time 
points. Such events should only be recorded once in the eCRF unless their severity increases. 
If a persistent AE becomes more severe or its sign or symptoms occur more frequently, the 
change in the severity grading, the date when th e severity change was reported,  and any new 
action taken shall be recorded in the eCRF.  
A recurrent AE occurs and resolves between subject evaluation time points and subsequently 
recurs. All recurrent AEs should be recorded individually on the AE eCRF.  
Abnor mal Laboratory Values  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 90 of 111 Only clinically significant laboratory abnormalities will be recorded as AEs on the eCRF and 
SAE form (if applicable).  
If the laboratory abnormality can be characterized by a precise clinical term, the clinical term 
should be recorde d as the AE or SAE. For example, an elevated serum potassium level of 
7.0 mEq/L should be recorded as “hyperkalemia”.  
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded as AEs on the  eCRF and SAE form (if applicable), unless 
their severity, seriousness, or etiology changes.  
Deaths  
All deaths that occur during the protocol -specified AE reporting period (see Section  8.5.1 ), 
regardless of attribution, will be recorded on the AE eCRF and SAE form and reported to the 
Sponsor within 24  hours of event knowledge.  
When recording a death, the event or condition that caused or contributed to the fatal outcome 
should be recorded as a single medical concept. For example, if death resulted from 
respi[INVESTIGATOR_1399], the AE recorded should be “Respi[INVESTIGATOR_60064]”, and the outcome of the  
AE would be “Death”. If the cause of death is unknown and cannot be ascertained at the time 
of reporting, record “unexplained death” on the AE eCRF and SAE form.  
Special Situations Reporting  
Medication errors and uses outside what is foreseen in the protocol, including overdose and 
occupational exposure must be reported to the Sponsor on an AE eCRF and an SAE form for 
tracking purposes and will be considered a protocol deviation. Additional instructions 
for reporting special situation information will  be provided by [CONTACT_680101].  
11.7.1  Assessment of Intensity  
The investigator will assess the intensity  (severity)  for each AE and SAE reported during the 
study and assign it to one of the following categories:  
• Mild:  
A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 91 of 111 • Moderate:  
A type of adverse event that is usually alleviated with additional specific therapeutic 
intervention.  The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research subject.  
• Severe:  
A type of adverse event that interrupts usual activities  of daily living, or significantly 
affects clinical status or may require intensive therapeutic intervention.   
11.7.2  Assessment of Causality  
The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE/d evice deficiency. The investigator will use clinical 
judgment to determine the relationship.  
The relationship will be determined by [CONTACT_25311] 
(Medical Device Coordination Group (MDCG) , 2020 ): 
• Not related : The relationship to the intervention can be excluded.  
• Possibly related : The relationship with the intervention is weak but cannot be ruled 
out completely. Alternative causes are also possible.  
• Probably related : The relationship with the intervention seems relevant and/or the 
event cannot reasonably be explained by [CONTACT_5748].  
• Causally related : The serious event is associated with the intervent ion beyond 
reasonable doubt.  
11.7.[ADDRESS_920250] the outcome of AEs and SAEs using the following criteria:  
 
Recovered/resolved:  The subject has fully recovered from the event, with no residual 
effects observable.  
Recovered/resolved with sequelae:  The subject has recovered from the event, but 
with residual sequelae effects observable.  
Not recovered/resolved:  Effects of the event ar e still present.  
Recovering/resolving:  The subject has improved but has not fully recovered from the 
event.  
Fatal:  The death is related to the event.  

OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 92 of 111 Unknown: The outcome of the event is unknown to the reporter ( e.g., the subject was 
lost to follow up).  
11.7.[ADDRESS_920251] of supplemental 
assessments  and/or evaluations as medically indicated or as requested by [CONTACT_47662]’s designee  to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
SAEs unrelated to study treatment and non -serious AEs are to be fol lowed until the last 
scheduled study visit (EOS visit), with the outcome at that point of time to be recorded in 
the eCRF. SAEs related to study treatment are to be followed up until resolution or until 
they return to baseline, stabilize, or the subject is  lost to follow -up. Resolution of AEs and 
SAEs (with dates) should be documented on the AE eCRF and SAE form (if applicable) 
and in the subject’s medical record to facilitate source data verification. For some SAEs, 
the Sponsor or its designee may follow u p by [CONTACT_756], facsimile, electronic mail, and/or 
a monitoring visit to obtain additional case details deemed necessary to appropriately 
evaluate the SAE report ( e.g., hospi[INVESTIGATOR_44458], consultant report, or autopsy 
report).  
If a subject dies d uring participation in the study or during a recognized follow -up period, 
the investigator will provide the sponsor or sponsor’s designee with a copy of any 
postmortem findings including histopathology.   
12 Regulatory Reporting Requirements (Serious Safety Ev ents, Safety Reporting in 
Clinical Investigations of Medical Devices, and DSUR)  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies (as applicable) about the safety of a study treatment under clinical 
investigation. The sponsor will comply with country -specific regulatory requirements related 
to safety reporting to the regulatory authority, IRBs , and investigators according to the 
regulations listed in  Section 8.5.[ADDRESS_920252] 
and medical device, and submission of the Drug Safety Update Report (DSUR) will be 
outlined in the Safety Management Plan and in accordance with the regulations listed in the 
Section 8.5.[ADDRESS_920253] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 93 of 111 12.1 Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  
For an event to be qualified as a suspected unexpecte d serious adverse reaction (S[LOCATION_003]R), the 
AE must meet three (3)  criteria:  
• the event is serious,  
• there is a reasonable possibility for the event to establish a causal relationship to the 
study drug being researched ( i.e., it qualifies adverse reaction), an d  
• the nature and severity of the reaction are not in agreement with the product 
information and the safety information in the IB ( i.e., the reaction is unexpected as per 
the reference safety information, i.e., the event is unexpected).  
All SUS ARs will be reported as required to the Competent Authorities and to the Institutional 
Review Boards (IRBs). In the US , this follows the requirements laid out in the US FDA 
guidance on safety reporting (US FDA, 2012 ). 
Following the definitions in 21 CFR 312.32(a), an adverse event or suspected adverse reaction 
is considered “unexpected” if it is not listed in the investigator brochure, or the SmPC of 
Triesence (US Version; (Alcon Laboratories Inc., 2007 ) or is not listed at the specificity or 
severity that has been observed. "Unexpected," as used in this definition, also refers to 
adverse events or suspected adverse reactions that are mentioned in the investigator brochure 
as occurring with a class of drugs or as anticipated from the pharmacological properties of the 
drug but are not specifically mentioned as occurring with the particular drug under 
investigation.

OXUCT -[ADDRESS_920254] ’s Experience Assessment  – Day 0, Visit [ADDRESS_920255]’s  Experience Assessment:  
Current and Procedure Pain & Discomfort  
 
To be completed by [CONTACT_680102] 0 / Visit 2  
Interviewer / completed by  
(print name)   
 
Instructions for the site interviewer:  Ask the study to subject  the questions below after the 
[ADDRESS_920256]  treatment measurement 
(e.g., OCT, IOP, etc.). Indicate the study subject ’s response by [CONTACT_680103].  
Instructions for the subject  (to be read to the subject  by [CONTACT_20679]):  Please answer the 
following questions about your experience of the procedure with the Oxulumis® device.   
 
Question 1:  Are you currently  experiencing pain in the procedure eye?  
☐ Yes 
☐ No  
Question 2:  Rate your current  level of pain in your procedure eye on a scale of 1 – 5 
☐ (1) No Pain  
☐ (2) Minimal Pain  
☐ (3) Mild Pain  
☐ (4) Moderate Pain  
☐ (5) Severe Pain  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 95 of 111 Question 3: Rate your pain during  the procedure  on a scale of 1 – 5 
☐ (1) No Pain  
☐ (2) Minimal Pain  
☐ (3) Mild Pain 
☐ (4) Moderate Pain  
☐ (5) Severe Pain  
Question  4 Rate your pain after completion  of the procedure  on a scale of 1 – 5 
☐ (1) No Pain  
☐ (2) Minimal Pain  
☐ (3) Mild Pain  
☐ (4) Moderate Pain  
☐ (5) Severe Pain  
Question 5: Are you currently  experiencing discomfort  in the procedure eye?  
☐ Yes  
☐ No  
Question 6: Rate your current  level of discomfort  in your procedure eye on a scale of 1 – 5 
☐ (1) No Discomfort  
☐ (2) Minimal Discomfort  
☐ (3) Mild Discomfort  
☐ (4) Moderate Discomfort  
☐ (5) Severe Discomfort  
Question  7: Rate your discomfort  during  the procedure  on a scale of 1 – 5  
☐ (1) No Discomfort  
☐ (2) Minimal Discomfort  
☐ (3) Mild Discomfort  
☐ (4) Moderate Discomfort  
☐ (5) Severe Discomfort  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 96 of 111 Question  8: Rate your discomfort  after completion  of the procedure  on a scale of 1 – 5  
☐ (1) No Discomfort  
☐ (2) Minimal Discomfort  
☐ (3) Mild Discomfort  
☐ (4) Moderate Discomfort  
☐ (5) Severe Discomfort  
 
Signature [CONTACT_50854] -
interviewer   
Date   
  
OXUCT -[ADDRESS_920257]’s Experience Assessment – Day 1, Visit [ADDRESS_920258]’s Experience Assessment:  
Current and Procedure Pain & Discomfort  
 
To be completed by [CONTACT_680104] (circle one)  ☐ Day 1 (Visit 3)  
☐ Day 7 (Visit 4 ) 
☐ Day 30 (Visit 5)  
Interviewer / completed by (print name)   
 
Instructions for site interviewer:  Ask the study to subject  the questions below. Questions can 
be asked at any time during the study visit and separated by [CONTACT_680105] ( e.g., OCT, IOP, etc.). Indicate the study 
subject ’s response by [CONTACT_680106].  
Instructions for study subject  (to be read to the subject  by [CONTACT_20679]):  Please answer the 
following questions about your current level of pain and discomfort in the eye which received 
the study treatment.   
Question 1:  Are you currently  experiencing pain in the procedure eye?  
☐ Yes 
☐ No  
Question 2:  Rate your current  level o f pain in your procedure eye on a scale of 1 – 5 
☐ (1) No Pain  
☐ (2) Minimal Pain  
☐ (3) Mild Pain  
☐ (4) Moderate Pain  
☐ (5) Severe Pain  
Question  3: Are you currently  experiencing discomfort  in the procedure eye?  
☐ Yes  
☐ No  
OXUCT -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 98 of 111 Question :  Rate your current  level of discomfort  in your procedure eye on a scale of 1 – 5 
☐ (1) No Discomfort  
☐ (2) Minimal Discomfort  
☐ (3) Mild Discomfort  
☐ (4) Moderate Discomfort  
☐ (5) Severe Discomfort  
 
 
Signature [CONTACT_50854] -
interviewer   
Date   
 
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI
5HWLQDOSK\VLFLDQ¶VGRFXPHQWDWLRQDQ GDVVHVVPHQWRIDGPLQLVWUDW LRQSURFHGXUH
5HWLQDOSK\VLFLDQ¶VGRFXPHQWDWLRQDQG
$VVHVVPHQWRIWKH2[XOXPLV$GPLQLVWUDWLRQ3URFHGXUH

,QWURGXFWLRQ
1RWHWKDWDQ\GLIILFXOW\RUFKDOOHQJH ZLWKWKHGHYLFHQRWHGEHO RZPD\TXDOLI\DVDQDGYHUVH
HYHQW$(RUDVDQDGYHUVHGHYLF HHIIHFW$'(DQGQHHGVWREH UHFRUGHGDVVXFKLQWKHVWXG\
GRFXPHQWDWLRQVRXUFHDQG&5)
2SHUDWLYH$VVHVVPHQW
$QWLVHSWLFDSSOLHGIRU'LVLQIHFWLRQ
3OHDVHVHOHFWZKLFKDQWLVH SWLFDJHQWKDVEHHQXVHG
3RYLGRQH,RGLQH
&KOR[LOCATION_006]H[LGLQH
2WKHU
,IRWKHUSOHDVHVSHFLI\

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB 
7\SHRI$QHVWKHVLDJLYHQ 
 :KLFKIRUPVRIDQHVWKHVLDZHUHDGPLQLVWHUHG"PRUHWKDQF KRLFHSRVVLEOH
7RSLFDO7HWUDFDLQHH\HGURSV
/LGRFDLQH*HO
6XEFRQMXQFWLYDO/LGRFDLQH
6XEWHQRQ/LGRFDLQH
2WKHUDOORZPRUHWKDQR QHHQWU\LQILHOGRWKHU
,IRWKHUSOHDVHVSHFLI\WKHGLVWDQFHLQPPHQWHUQXPEHU

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB 
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI ,IVXEFRQMXQFWLYDOSOHDVHVSHFLI\TXDGUDQWZKHUHDSSOLHG PRUHWKDQVHOHFWLRQ
SRVVLEOH
VXSHULRU±WHPSRUDO
VXSHULRUQDVDO
LQIHULRUWHPSRUDO
LQIHULRUQDVDO
 ,IVXEWHQRQSOHDVHVSHFLI\TXDGUDQWZKHUHDSSOLHGPRUH WKDQVHOHFWLRQSRVVLEOH
VXSHULRU±WHPSRUDO
VXSHULRUQDVDO
LQIHULRUWHPSRUDO
LQIHULRUQDVDO
([HFXWLRQRIWKH2[XOXPLV3URFHGXUH 
 :DVWKHSURFHGXUHSHU IRUPHGVXFFHVVIXOO\LQWKHILUVWDWWHP SW"
<HV
1R
 ,I 1RSOHDVHWLFNDOODSSOLFDEOH
&RXOGQRWRURQO\LQVXIILFLHQWO\HQJDJH VFOHUDZLWKWKHEHYHO
,FRXOGHQJDJHWKHVFOHUDEXWW KHFDWKHWHUGLGQRWGHSOR\
7KHFDWKHWHUGHSOR\HGVXEFRQMXQFWLYDOO\
7KHFDWKHWHUGHSOR\HGLQWUDYLWUHDOO\
2WKHU
,IRWKHUSOHDVHVSHFLI\
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 +RZPDQ\GLIIHUHQWGHYLFHVQH HGHGWREHXVHGXQWLOVXFFHV VIXOFRPSOHWLRQRIWKH
SURFHGXUH"



 ,IRULVWLFNHGSOHDVHEULHIO\VX[COMPANY_003]UL]H

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI 3URYLGHDUHDVRQIRU H[FKDQJLQJ'HYLFH

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 3URYLGHDUHDVRQIRU H[FKDQJLQJ'HYLFH

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB

/RFDWLRQRIWKH,QVHUWLRQ3RLQW 
 :KLFK4XDGUDQWZDVFKRVHQ"
VXSHULRU±WHPSRUDO
VXSHULRUQDVDO
LQIHULRUWHPSRUDO
LQIHULRUQDVDO
 $WZKLFKGLVWDQFHIURPWKHOLPEXVZDVWKHWURFDULQVHUWHG"
3OHDVHWLFNWKHULJKWFDWHJRU\
PP
PP
2WKHU
,IRWKHUSOHDVHVSHFLI\WKH GLVWDQFHLQPPHQWHUQXPEHU

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBB
 ,QVHUWLRQ 
 $WZKLFKDQJOHUHODWLYHWRWKHVXUI DFHRIWKHH\HZDVWKHW URFDULQVHUWHGLQWRW KHVFOHUD"
o
o
o
o!
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI %HYHORULHQWDWLRQ
x8S
x6LGHZD\VOHIW
x6LGHZD\VULJKW
x'RZQ
 ,QVHUWLRQFRPSOHWHGWKURXJKWKHVFOHUD
<HV
1R
 'LIILFXOW\WLFNDVDSSURSULDWHRUGURSGRZQ
YHU\HDV\
HDV\
VRPHZKDWHDV\
GLIILFXOW
YHU\GLIILFXOW
 &RPSOLFDWLRQVWLFNDVDSSOLFDEOH
1RFRPSOLFDWLRQV
,QVHUWLRQQHHGOHFRXOGKDUGO\SDVVWKHVFOHUD
&DWKHWHUGLUHFWO\GHSOR\HGZKHQWULJJH USUHVVHGQRIXUWKHUDGY DQFHPHQW
QHFHVVDU\
2WKHU
,IRWKHUSOHDVHVSHFLI\

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBB
 'HSOR\PHQW 
 :DVWKHGHSOR\PHQWRIWKH FDWKHWHUWRWKHVXSUDFKRURLGDOVS DFHFRPSOHWHGDV
LQWHQGHG"
<HV
1R


2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI )URPGHSOR\HGPLFURFDWKHWHU: DVWKHOLJKWYLVLEOHDVH[SHF WHGDQGVXIILFLHQWO\
EULJKW"
<HV
1R
 :DVWKHVSHHGRIGHSOR\PHQWGXU LQJWKHSURFHGXUHDVVHWLQL WLDOO\"
<HV
1R
 $Q\NLQNLQWKHWXELQJ"
<HV
1R
 ,I 
$Q\NLQNLQWKHWXELQJ
LVWLFNHGµ <HV¶SOHDVHSURYLGHGHWDLOVDQGSUHVXPHG
UHDVRQ"

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB B
 ,QMHFWLRQRIGUXJYLDWKHGUXJOLQH 
 :DVWKHLQMHFWLRQFRPSOHWHGDVH[SHFWHG"
<HV
1R
 ,I 1RSOHDVHWLFNDVDSSURSULDWH
0LFURFDWKHWHUFORJJHGE\GUXJD QGLQMHFWLRQFRXOGQRWEHFRPSOH WHG
2WKHUSOHDVHVSHFLI\

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBB
 :KDWZDVWKHWLPHLQWHUYD OIRUWKHGUXJLQMHFWLRQ"
/HVVWKDQVHF
VHF
VHF
VHF
VHF
/RQJHUWKDQVHF
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI :KDWZDVWKHUHVLGHQFHWLPH RIWKHFDWKHWHULQWKHVXSUDFKR URLGDOVSDFHDIWHU
FRPSOHWLRQRIWKHLQMHFWLRQ"
/HVVWKDQVHF
VHF
VHF
VHF
VHF
/RQJHUWKDQVHF
 'LGWKHSDWLHQWIHHOSDLQGXULQJWKHLQMHFWLRQ"
<HV
1R
 ,I <HVZKHQGLGWKHSDLQVWDUW
:LWKWKHLQVHUWLRQQHHGOH¶V WLSLQVHUWHGLQWRWKHVFOHUD
:LWKWKHLQVHUWLRQQHHGOH¶V DGYDQFHPHQWLQWRWKHVFOHUD
:LWKFDWKHWHUGHSOR\PHQW
:LWKPHGLFDWLRQLQMHFWLRQ
:LWKFDWKHWHUZLWKGUDZDO
$IWHUSURFHGXUHFRPSOHWLRQ
2WKHUSOHDVHVSHFLI\
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 +RZORQJGLGWKHSDLQODVW"
(QWHUGXUDWLRQLQPLQXWHVBBBBBBBBBBBBBB
 :DVDQ\PHGLFDWLRQRULQWHUYHQWL RQSHUIRUPHGWRDOOHYLDWHS DLQ"
<HV
1R
 ,I <HVVSHFLI\
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 :KHUHLVWKHLQMHFWLRQORFDWHGLQUHODWLRQWRWKHPDMRUUHW LQDOODQGPDUNV"3OHDVHWLFN
DOOWKDWDSSO\
LQVHUWLRQSRLQW
DUFDGHV
DQWHULRUWRHTXDWRU
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRIHTXDWRU
SRVWHULRUWRHTXDWRU
RSWLFQHUYH
2WKHUSOHDVHVSHFLI\

 $Q\UHIOX["
<HV
1R
,I<HVVSHFLI\
 YHU\PLOG
 PLOGWR
 VRPHZKDW
 0DUNHG
 9HU\0DUNHGDQGPRUH

 'LIILFXOW\WRLQMHFWWKHVWXG\GUXJ
YHU\HDV\
HDV\
VRPHZKDWHDV\
GLIILFXOW
YHU\GLIILFXOW
 &RPSOLFDWLRQV
<HV
1R
,I
&RPSOLFDWLRQV
LVHTXDOWR
 <HV
DQVZHUWKLVTXHVWLRQ
7LFNDOO&RPSOLFDWLRQVWKDWDSSO\
,QWUDYLWUHDOGUXJGHSRVLW
&RQMXQFWLYDOGUXJGHSRVLW
'LVFRQQHFWRI0HULWV\ULQJH
&DWKHWHUFORJJHGE\7ULHVHQFH
2WKHU
,IRWKHUSOHDVHVSHFLI\

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI %OHHGLQJ 
 $Q\LQWUDRFXODUEOHHGLQJ"
<HV
1R
 ,I
$Q\LQWUDRFXODUEOHHGLQJ
LVHTXDOWR
 <HV
DQVZHUWKLVTXHVWLRQ
 /RFDOL]DWLRQRIWKHEOHHGLQJ
YLWUHRXV
UHWLQDO
VXEUHWLQDO
&KRURLGDOVXSUDFKRURLGDO
,I
$Q\LQWUDRFXODUEOHHGLQJ
RFFXUUHGSOHDVHSURYLGHGHWDLOV
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB B
 $Q\VFOHUDOGDPDJH"
<HV
1R
,I
$Q\VFOHUDOGDPDJH
RFFXUUHGSOHDVHSURYLGHGHWDLOV

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB 
3OHDVHFRPPHQW
 $Q\RWKHUGDPDJHSOHDVHWLFNWKHRQHVWKDWDSSO\
7UDXPDWLFFDWDUDFW
5HWLQDOGHWDFKPHQW
5HWLQDOKROH
2WKHU
,IRWKHUSOHDVHVSHFLI\
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI
*XLGDQFHRQ)DFWRUVWR&RQVLGHUIRU ([SHFWHG$VVHVVPHQWRI3URF HGXUDO
&RPSOH[LW\
,QGLYLGXDOVXEMHFWIDFWRUVPD\ YDU\ZLGHO\EHWZHHQVXEMHFWV7K LVPD\LPSDFWWKHSURFHGXUDO
FRPSOH[LW\RIWKH2[XOXPLVLOOXPLQDWHGPLFURFDW KHWHUL]DWLRQ
,QVXEMHFWVZLWKIDFWRUVLQGLFDWLQJDSRWHQWLDOO\KLJKH[SHFWHG FRPSOH[LW\RISHUIRUPLQJWKH
2[XOXPLVSURFHGXUHWKHLQYHVWLJDWRUPD\GHF LGHWRSUHHPSWLYHO\SHUIRUP WKHSURFHGXUH
GLUHFWO\LQDQRSHUDWLQJSURFHGXUH URRPZLWKWKHSURFHGXUDOYDU LDQWLQFOXGLQJD
FRQMXQFWLYDOWHQRQLQFLVLRQWRSRWHQWLDOO\ID FLOLWDWHVFOHUDOH QJDJHPHQW
7KLVVXEMHFWLYHLQYHVWLJDWRUDVVHVVPHQWKD VWREHSHUIRUPHGDW VFUHHQLQJ
1RWH6LJQLILFDQWVFOHUDOD EQRUPDOLWLHVQHHGWREHDVVHVVHGIRU SRWHQWLDOO\OHDGLQJWRQRQ
HOLJLELOLW\SHUH[F OXVLRQFULWHULRQ1R
$OVRQRWHWKDWZLWKDQDVVHVVPHQWRI H[SHFWHGKLJKSURFHGXUDOF RPSOH[LW\H[FOXVLRQFULWHULRQ
1RPXVWQRWEHPHW LHQHLWKHUFRQGLWLRQVL QWKHVWXG\H\HWKDWPD\UHQGHUWKH
VXSUDFKRURLGDOPLFURFDWKHWHULQVHU WLRQDQGGHSOR\PHQWGLIILFXOW HYHQZLWKVFOHUDOLQFLVLRQ
VKRXOGEHSUHVHQWQRUWKHULVNVRIFRPSOLFDWLRQVIRUDSDWLHQW VKRXOGEHH[FHVVLYH

)DFWRU+LVWRU\0HGLFDWLRQ &RPSOH[LW\
)DFLDO6NXOO$QDWRP\   
x&RQILJXUDWLRQRIWKHRUELWD"$FFHVV" /RZ0HGLXP +LJK
x&RQILJXUDWLRQRIIRUHKHDG"
3URPLQHQFHRIWKHEURZULGJH"/RZ0HGLXP +LJK
x%OHSKDURSWRVLV"([FHVVLYHH\H OLGVNLQGHUPDWRFKDODVLV" /RZ0HGLXP +LJK
x2WKHUSOHDVHVSHFLI\ /RZ 0HGLXP +LJK
&RQMXQFWLYD7HQRQ   
x$JH"QRWHKLJKHUDJHPD\EH FRUUHODWHGZLWKWKLQQHU
FRQMWHQRQ/RZ0HGLXP +LJK
x7KLFNQHVVRI&RQM7HQRQ"2SDFLW\"0RELOLW\" /RZ0HGLXP +LJK
x0HGLFDO+LVWRU\RI&RQM7H QRQDEQRUPDOLWLHV HJ
&KURQLFEOHSKDULWLV"7R[LFFRQMXQFWLYLWLV HJGXHWR/RZ0HGLXP +LJK
2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRIFKURQLFXVHRIH\HGURSV"$OOHU JLFFRQMXQFWLYLWLV"6HYHUH
GU\H\HGLVHDVH"2FXODUSHPSKLJRLG"
1RWHSHUH[FOXVLRQFULWH ULRQ1RRFXODUVXUIDFH
GLVHDVHVZLWKVLJQLILFDQW FRQMXQFWLYDOHGHPDDQGRU
LQIOD[COMPANY_003]WLRQDUHH[FOXVLRQDU\
x0HGLFDWLRQZLWKLPSDFWRQFRQMWHQRQWKLFNQHVVQRWH
PHGLFDWLRQVZLWKFRQM WKLQQLQJORQJWHUPHIIHFWVPD\
DOORZEHWWHUVFOHUDOYLVXDOL]DWLRQZKLOHWKRVH FDXVLQJ
LQFUHDVHGWKLFNQHVVGXHW RFKURQLFLQIOD[COMPANY_003]WLRQ
LQFUHDVHGYDVFXODUL]DWLR QRUFKHPRVLVZRUVHQV
YLVXDOL]DWLRQ/RZ0HGLXP +LJK
x2WKHUSOHDVHVSHFLI\ /RZ 0HGLXP +LJK
6XUJLFDOKLVWRU\   
x,QFLVLRQDOJODXFRPDVXU JHU\"$FFHVVLQVXSHULRU
WHPSRUDOTXDGUDQW"6FDUULQJ"/RZ0HGLXP +LJK
x([WUDFDSVXODUFDWDUDFWVXUJH U\"$FFHVVLQVXSHULRU
WHPSRUDOTXDGUDQW"6FDUULQJ"/RZ0HGLXP +LJK
x2WKHURFXODUVXUJHULHV HJVTXLQWVXUJHU\RU
FRQMXQFWLYDOSHULWRP\ ZLWKSRWHQWLDOLPSDFWRQVFOHUDO
DFFHVVLQ WKHVXSHULRUWHPSRUDOTXDGUDQWSO HDVHVSHFLI\/RZ 0HGLXP +LJK

&RQFOXVLRQ
2YHUDOO$VVHVVPHQWRI([SHFWHG3URFHGXUDO&RPSOH[LW\([SHUW-X GJPHQW
7KH2[XOXPLV3URFHGXUHLQWKHFXUU HQWVXEMHFWVLVH[SHFWHGWRK DYH
/RZ
0HGLXP
+LJK
&RPSOH[LW\


2;8&7&OLQLFDO7ULDO3URWRFRO9)HE 2[XODU/LPLW HG
 &RQILGHQWLDO SDJHRI7KHSURFHGXUHLVWKHUHIRUHSODQQH GWREHSHUIRUPHGSOHDVHWLFN DSSOLFDEOH

,QDQLQFOLQLFVHWWLQJ 2QO\LIQRWFRPSOHWHGDWUHDWPHQWDWWHPSWZLWKD
FRQMXQFWLYDOWHQRQLQFLVLRQLVSODQQHGLQDQ □RSHUDWLQJ □SURFHGXUHURRPVHWWLQJ
,QDSURFHGXUHURRP 2QO\LIQRWFRPSOHWHGDWUHDWPHQWDWWHPSWZLWKD
FRQMXQFWLYDOWHQRQLQFLVLRQLVSODQQHGRSHUDWLQJURRPVHWWLQJ 
,QDQ□RSHUDWLQJ □SURFHGXUHURRP ZLWKDVHWWLQJDOORZLQJDFRQMXQFWLYDOWHQRQ
LQFLVLRQLIQHHGHG

GHSHQGLQJRQWKHORFDWLRQRIWKHLQYHVWL JDWLRQDOVLWHSURFHGX UHURRPVPD\DOVREH
VXIILFLHQWO\HTXLSSHGWRSHUIRUPSU RFHGXUHVOLNHFRQMXQFWLYDOW HQRQLQFLVLRQVDQGWKHLUFORVXUH
E\VXUJLFDO HJILEULQJOXHRUVXWXULQJ

OXUCT -103 Clinical Trial Protocol V3.0 15 Feb 2023  Oxular Limited  
 Confidential  page 110 of 111 
 14 References  
Alcon Laboratorie s Inc. 2007. 'TRIESENCE ™ (triamcinolone acetonide injectable 
suspension) 40 mg/mL - US Prescribing Information': 1 -12. 
Bandoli , G., K. Palmsten, C. J. Forbess Smith, and C. D. Chambers. 2017. 'A Review of 
Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth 
Outcomes', Rheum Dis Clin North Am , 43: 489 -502. 
Barakat, M. R., C. C. Wykoff, V. Gonzalez, A . Hu, D. Marcus, E. Zavaleta, and T. A. Ciulla. 
2021. 'Suprachoroidal CLS -TA plus Intravitreal Aflibercept for Diabetic Macular 
Edema: A Randomized, Double -Masked, Parallel -Design, Controlled Study', 
Ophthalmol Retina , 5: 60 -70. 
Boyer, D. S., Y. H. Yoon, R . Belfort, Jr., F. Bandello, R. K. Maturi, A. J. Augustin, X. Y. Li, 
H. Cui, Y. Hashad, S. M. Whitcup, and Mead Study Group Ozurdex. 2014. 'Three -
year, randomized, sham -controlled trial of dexamethasone intravitreal implant in 
patients with diabetic macula r edema', Ophthalmology , 121: 1904 -14. 
Campochiaro, P. A., C. C. Wykoff, D. M. Brown, D. S. Boyer, M. Barakat, D. Taraborelli, G. 
Noronha, and Group Tanzanite Study. 2018. 'Suprachoroidal Triamcinolone 
Acetonide for Retinal Vein Occlusion: Results of the T anzanite Study', Ophthalmol 
Retina , 2: 320 -28. 
Chang, T. S. 2009. 'Suprachoroidal Drug Delivery via Catheter: A Medico -Surgical Approach 
to Wet AMD', Retina Summit [ADDRESS_920259] Book : 1-5. 
Clinical Trials Facilitation and Coordination Group. 2020. 'Recomme ndations related to 
contraception and pregnancy testing in clinical trials', Heads of Medicines Agencies 
Homepage : 1-10. 
Ehlers, J. P., S. Yeh, M. G. Maguire, J. R. Smith, P. Mruthyunjaya, N. Jain, L. A. Kim, C. Y. 
Weng, C. J. Flaxel, S. D. Schoenberger, a nd S. J. Kim. 2022. 'Intravitreal 
Pharmacotherapi[INVESTIGATOR_680056]: A Report by [CONTACT_679458]', Ophthalmology , 129: 88 -99. 
European Parliament/Council (EC). 2017. 'REGULATION (EU) 2017/745 OF THE 
EUROPEAN PARLIAMENT AND OF THE COUNCIL on medical devices', Official 
Journal of the European Union : 1-175. 
Medical Device Coordination Group (MDCG). 2020. 'Safety reporting in clinical 
investigations of medical devices under the Regulation (EU) 2017/745': 1 -16. 
Olsen, T. W., X. F eng, K. Wabner, S. R. Conston, D. H. Sierra, D. V. Folden, M. E. Smith, 
and J. D. Cameron. 2006. 'Cannulation of the suprachoroidal space: a novel drug 
delivery methodology to the posterior segment', Am J Ophthalmol , 142: 777 -87. 
Patel, S. R., D. E. Berezo vsky, B. E. McCarey, V. Zarnitsyn, H. F. Edelhauser, and M. R. 
Prausnitz. 2012. 'Targeted administration into the suprachoroidal space using a 
microneedle for drug delivery to the posterior segment of the eye', Invest Ophthalmol 
Vis Sci , 53: 4433 -41. 
Pearce, W., J. Hsu, and S. Yeh. 2015. 'Advances in drug delivery to the posterior segment', 
Curr Opin Ophthalmol , 26: 233 -9. 
Price, K. W., T. A. Albini, and S. Yeh. 2020. 'Suprachoroidal Injection of Triamcinolone - 
Review of a Novel Treatment for Macular E dema Caused by [CONTACT_680107]', 
US Ophthalmic Rev , 13: 76 -79. 
Qamar, R. M., M. I. Saleem, and M. F. Saleem. 2013. 'Comparison of the efficacy between an 
intravitreal and a posterior subtenon injection of triamcinolone acetonide for the 
treatment of diffuse diabetic macular edema', Eurasian J Med , 45: 185 -90. 
Qi, H. P., S. Bi, S. Q. Wei, H. Cui, and J. B. Zhao. 2012. 'Intravitreal versus subtenon 
triamcinolone acetonide injection for diabetic macular edema: a systematic review and 
meta -analysis', Curr  Eye Res , 37: [ADDRESS_920260] -103 Clinical Trial Protocol V 3.0 17-Feb-2023  Oxular Limited  
 Confidential  page 111 of 111 Rittiphairoj, T., T. A. Mir, T. Li, and G. Virgili. 2020. 'Intravitreal steroids for macular edema 
in diabetes', Cochrane Database Syst Rev , 11: CD005656.  
Rizzo, S., F. G. Ebert, E. D. Bartolo, F. Barca, F. Cresti, C. Augustin, and A . Augustin. 2012. 
'Suprachoroidal drug infusion for the treatment of severe subfoveal hard exudates', 
Retina , 32: 776 -84. 
Shah, J., A. Vaze, T. Tang Lee Say, M. C. Gillies, and S. Fraser -Bell. 2020. 'Emerging 
corticosteroid delivery platforms for treatment  of diabetic macular edema', Expert 
Opin Emerg Drugs , 25: 383 -94. 
Tetz, M., S. Rizzo, and A. J. Augustin. 2012. 'Safety of submacular suprachoroidal drug 
administration via a microcatheter: retrospective analysis of European treatment 
results', Ophthalmolo gica, 227: 183 -9. 
Udaondo, P., A. Adan, L. Arias -Barquet, F. J. Ascaso, F. Cabrera -Lopez, V. Castro -Navarro, 
J. Donate -Lopez, A. Garcia -Layana, F. J. Lavid, M. Rodriguez -Maqueda, and J. M. 
Ruiz -Moreno. 2021. 'Challenges in Diabetic Macular Edema Management : An Expert 
Consensus Report', Clin Ophthalmol , 15: 3183 -95. 
US FDA. 2012. 'Safety Reporting Requirements for INDs and BA/BE Studies - Guidance for 
Industry and Investigators': 1 -32. 
US FDA. 2021a. 'Investigator Responsibilities -Safety Reporting for Investigational Drugs 
and Devices  - (Draft) Guidance for Industry': 1 -14. 
US FDA. 2021b. 'Sponsor Responsibilities - Safety Reporting Requirements and Safety 
Assessment for IND and Bioavailability/Bioequivalence Studies - Draft Guidance for 
Industry': 1 -44. 
Wilkins, C. S., E. K. Sobol, G. M. Lema, J. G. Lee, R. B. Rosen, and A. Deobhakta. 2021. 
'Intravitreal dexamethasone insert in diabetic macular edema super -refractory to anti -
vascular endothelial growth factor therapy', Eur J Ophthalmol : 112067212110043 91. 
Wykoff, C. C., R. N. Khurana, S. I. R. Lampen, G. Noronha, D. M. Brown, W. C. Ou, S. R. 
Sadda, and Hulk Study Group. 2018. 'Suprachoroidal Triamcinolone Acetonide for 
Diabetic Macular Edema: The HULK Trial', Ophthalmol Retina , 2: 874 -77. 
Yeh, S., R. N.  Khurana, M. Shah, C. R. Henry, R. C. Wang, J. M. Kissner, T. A. Ciulla, G. 
Noronha, and Peachtree Study Investigators. 2020. 'Efficacy and Safety of 
Suprachoroidal CLS -TA for Macular Edema Secondary to Noninfectious Uveitis: 
Phase 3 Randomized Trial', Ophthalmology , 127: 948 -55. 
Zur, D., M. Iglicki, and A. Loewenstein. 2019. 'The Role of Steroids in the Management of 
Diabetic Macular Edema', Ophthalmic Res , 62: 231 -36. 
 